



Review

# Vimentin as a Multifaceted Player and Potential Therapeutic Target in Viral Infections

Irene Ramos <sup>1</sup>, Konstantinos Stamatakis <sup>2</sup> , Clara L. Oeste <sup>2</sup> and Dolores Pérez-Sala <sup>3,\*</sup>

<sup>1</sup> Department of Neurology and Center for Advanced Research on Diagnostic Assays, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; irene.ramos.lopez@gmail.com

<sup>2</sup> Centro de Biología Molecular Severo Ochoa, UAM-CSIC. Nicolás Cabrera, 1, Campus de la Universidad Autónoma de Madrid, 28049 Madrid, Spain; k.s@csic.es (K.S.); oeste@cbm.csic.es (C.L.O.)

<sup>3</sup> Department of Structural and Chemical Biology, Centro de Investigaciones Biológicas Margarita Salas, CSIC, Ramiro de Maeztu, 9, 28040 Madrid, Spain

\* Correspondence: dperezsala@cib.csic.es

Received: 6 June 2020; Accepted: 29 June 2020; Published: 30 June 2020



**Abstract:** Vimentin is an intermediate filament protein that plays key roles in integration of cytoskeletal functions, and therefore in basic cellular processes such as cell division and migration. Consequently, vimentin has complex implications in pathophysiology. Vimentin is required for a proper immune response, but it can also act as an autoantigen in autoimmune diseases or as a damage signal. Although vimentin is a predominantly cytoplasmic protein, it can also appear at extracellular locations, either in a secreted form or at the surface of numerous cell types, often in relation to cell activation, inflammation, injury or senescence. Cell surface targeting of vimentin appears to associate with the occurrence of certain posttranslational modifications, such as phosphorylation and/or oxidative damage. At the cell surface, vimentin can act as a receptor for bacterial and viral pathogens. Indeed, vimentin has been shown to play important roles in virus attachment and entry of severe acute respiratory syndrome-related coronavirus (SARS-CoV), dengue and encephalitis viruses, among others. Moreover, the presence of vimentin in specific virus-targeted cells and its induction by proinflammatory cytokines and tissue damage contribute to its implication in viral infection. Here, we recapitulate some of the pathophysiological implications of vimentin, including the involvement of cell surface vimentin in interaction with pathogens, with a special focus on its role as a cellular receptor or co-receptor for viruses. In addition, we provide a perspective on approaches to target vimentin, including antibodies or chemical agents that could modulate these interactions to potentially interfere with viral pathogenesis, which could be useful when multi-target antiviral strategies are needed.

**Keywords:** vimentin; cell surface vimentin; SARS-CoV; vimentin–pathogen interactions; anti-vimentin autoantibodies; inflammation; intermediate filaments; posttranslational modifications; tissue damage and repair; immune response

## 1. Introduction

Vimentin is a type III intermediate filament cytoskeletal protein expressed mainly in cells of mesenchymal origin. Therefore, it is present in fibroblasts, endothelial cells, and cells of the immune system. Vimentin filaments form a network that extends from the nuclear periphery towards the plasma membrane of cells. Vimentin carries out or modulates a plethora of cellular functions. Once thought to be dispensable due to the viability and fertility of vimentin knockout mice, it is now recognized that vimentin plays key roles in cell architecture and dynamics. Vimentin filaments interact with and modulate the function of other cytoskeletal components, and act as integrators of cellular mechanical

functions, including cell migration, adhesion and division [1–4]. Vimentin also works in organelle position and homeostasis [5–7], aggresome formation [6,8], and protection of the nucleus in situations of mechanical stress [9]. Furthermore, it plays important roles in cell signaling by regulating the localization and activity of several MAP kinases, lipid metabolism, and even gene expression [10].

Extensive research in vimentin-deficient animal models has unveiled its involvement in response to injury or stress, with implications in wound healing, inflammation and immune response, atherosclerosis, fibrosis or infection [11–14]. Indeed, vimentin is also involved in pathology, as exemplified by its increased levels and function in fibrosis [15,16], tumorigenic transformation and tumor cell invasiveness [17,18], as well as by its role as an autoantigen in autoimmune diseases and as a receptor for pathogens [19,20] (please see [21,22] for review).

Given its implications in pathology, vimentin has become an important drug target. Nevertheless, the approaches available to harness its participation in disease are still limited. Infections by antibiotic-resistant bacteria or by newly disseminated viruses constitute global health challenges. In spite of continued research on these topics, unexpected outbreaks of infectious diseases highlight the need for new therapeutic tools. In the fight against novel pathogens, multiple targeting and combined treatments become necessary. The purpose of this review is to investigate the abundant evidence on vimentin involvement in infection and associated damage and hypothesize about its potential interest as an additional therapeutic target against certain viral infections.

## 2. General Concepts on Vimentin Structure and Assembly

The vimentin monomer is an ~54 kDa protein with a rod shape that is constituted by four alpha-helical segments joined by linkers and flanked by disorganized head (N-terminal) and tail (C-terminal) domains [23]. Although the crystal structure of the full-length protein is not yet available, numerous works employing a great variety of structural techniques have provided valuable information on vimentin organization and assembly [24–27]. Several excellent reviews have covered this topic [10,23,28], and therefore, it will be briefly considered here. The sequence of events of vimentin assembly has been deduced from exhaustive *in vitro* studies. Vimentin monomers possess intrinsic structural features that drive their immediate association into parallel dimers. Tetramers would then form by the anti-parallel half-staggered dimerization of two dimers. Finally, eight tetramers assemble to give rise to what is known as a unit-length filament (ULF). These ULFs associate head to tail in the elongation process, which would be followed by a radial compaction process yielding mature filaments of approximately 12 nm of width. Whereas the head domain is essential for tetramer formation and filament assembly, the tail domain appears to modulate filament compaction and bundling [29]. Vimentin polymerizes in solutions of physiological ionic strength *in vitro* and is mostly polymerized in non-mitotic cells [23,30]. Nevertheless, the assembly and organization of vimentin filaments in cells have not been completely elucidated. It has been proposed that vimentin filament precursors (ULFs) are transported by molecular motors on microtubules and fuse with additional units to form short filaments or squiggles, which later anneal head to tail to form filaments [31]. Moreover, filaments can associate laterally to form bundles. In addition, vimentin polymerization differs from that of tubulin or actin in that it is non-polar (it can take place at either end of the filament), subunit exchange can occur at any point along the length of the filament, and it does not require nucleotide binding. Indeed, constant exchange between soluble and polymerized vimentin occurs in cells, allowing fast and versatile remodeling of the network in response to physiological stimuli or to various kinds of stress.


The plasticity and dynamics of the intracellular vimentin network is highly dependent on the regulation of the disassembly process, which is driven by posttranslational modifications (PTMs), mainly phosphorylation [32]. In addition, modifications occurring under oxidative stress play an important role in the reorganization of the vimentin network [6,33]. Vimentin possesses a single cysteine residue (C328) that is the target for PTMs that impact its organization *in vitro* and in cells [34,35]. C328 is required for vimentin network remodeling in response to oxidants and electrophiles, thus acting as a sensor for these conditions, which may have pathophysiological implications [6]. Moreover,

modifications at C328 can cooperate with other PTMs, such as phosphorylation, to induce filament disassembly [35]. Interestingly, cells expressing a C328S vimentin mutant display several functional defects, which highlights the involvement of this protein in multiple cellular processes [6]. In addition to phosphorylation and oxidative modifications, vimentin is the target of numerous PTMs with diverse consequences on its organization [32]. Relevant to this review are also glycosylation [36] and proteolysis. Vimentin proteolytic cleavage, either by endogenous proteases, like caspases during apoptosis [37] or calpain during hypotonic stress [38], or by proteases from pathogens, like the Moloney mouse sarcoma virus [39] or human immunodeficiency virus (HIV) [40], can provoke drastic rearrangements of the vimentin network with implications in pathogenesis.

Therefore, vimentin can exist in different assembly states in cells, which can exert distinct actions in critical cellular processes, through mechanisms not completely elucidated.

### 3. Extracellular Vimentin

Vimentin is an important component of the cytoplasmic structural networks. Nevertheless, accumulating evidence situates vimentin at the cell surface or in the bloodstream, either as “soluble” forms or as a vesicle-transported protein, implying important roles in the extracellular milieu (Figure 1). Among other conditions, cell activation, apoptosis, senescence, inflammation and stress can elicit vimentin secretion [14,41].



**Figure 1.** Multifaceted roles of extracellular vimentin. Vimentin, apparently in an oligomeric form, can be exposed at the surface of certain cell types, under normal and/or certain pathophysiological conditions. Additionally, vimentin can be secreted, putatively in soluble and vesicle-bound forms. For the purpose of this review, both secreted and cell-surface exposed forms will be considered extracellular vimentin. At these extracellular locations, vimentin is involved in multiple interactions and pathophysiological processes related to immune cell activation, autoimmune disease, wound healing and tissue damage, cell migration, and pathogen recognition and entry or restriction. The vimentin species participating in these diverse effects are not fully characterized and further research is needed to ascertain whether there are structure–function relationships determining these pleiotropic actions. See text for details. CSV, cell surface vimentin; IGF-1R, insulin-like growth factor 1 receptor; N-AcGln, N-acetylglucosamine; PAI-1, plasminogen activator inhibitor; PTMs, posttranslational modifications.

Vimentin can be exposed at the surface or secreted by several cell types, including activated macrophages [14] and neutrophils [42], endothelial cells (HUVEC and brain microvascular endothelial

cells) [43,44], and platelets [45]. Extracellular vimentin has been involved in a variety of processes, including cell–cell interaction, hemostasis, immune activation, interaction with pathogens and tissue repair (see below). Nevertheless, the mechanisms of transport to the cell surface or secretion, the structural features of extracellular vimentin, either secreted or membrane-bound, and the involvement of specific PTMs in vimentin exposure require further investigation.

Vimentin secreted by activated macrophages was reported to be phosphorylated at serine and threonine residues, and phosphatase and kinase inhibitors stimulated or inhibited secretion, respectively, thus suggesting the importance of phosphorylation in this process [14,46]. Among pathophysiological stimuli, secretion was stimulated by oxidized low-density lipoproteins [47] and TNF $\alpha$  and inhibited by IL-10. In this vein, Avram et al. showed that phorbol esters or cytokine activation of neutrophils stimulated the generation of tyrosyl radicals, inducing tyrosylation of various proteins, including membrane-bound extracellular vimentin [48]. In addition, upon activation, vimentin appeared as a 2D electrophoresis-resistant dimer (120 kDa apparent electrophoretic mobility) that was both tyrosylated, at undefined sites, and phosphorylated at the tail domain (T426) [48]. In turn, phosphorylation of the head domain at S72 has been shown to associate with vimentin recruitment to the cell surface upon treatment with N-acetyl-glucosamine (N-AcGln) polymers [49], thus strengthening the importance of PTM for vimentin exposure. Interestingly, extracellular exposure of the protein is frequently associated with oxidative stress [42]. Consistent with this, oxidative modifications and electrophile addition have also been reported on extracellular vimentin [33]. Vimentin exposed by CHO cells was shown to be, at least in part, reversibly oxidized [50], whereas that released by RAW264.7 macrophages stimulated with LPS has been shown to be glutathionylated [51]. In turn, vimentin exposed at the surface of human senescent fibroblasts and in plasma of aged senescence-accelerated mice was modified by addition of the electrophilic lipid malondialdehyde to C328 [41], which led these authors to propose that malondialdehyde-modified vimentin could behave as a signal for recognition and elimination of senescent cells by the immune system. In addition, since exposed vimentin is frequently oxidized, it has been proposed that it could contribute to a cascade amplifying the immune response and damage [52]. Indeed, extracellular vimentin has been reported to induce macrophage release of proinflammatory cytokines and contribute to atherosclerotic inflammation [47]. On the other hand, vimentin exposed by neutrophils undergoing spontaneous apoptosis appears to correspond to a caspase-cleaved form that retains the C-terminal domain [53].

An important modification of extracellular vimentin is citrullination, which occurs in both physiological and pathological conditions [54,55]. This is an enzymatic modification catalyzed by peptidyl arginine deiminases [56] that turns vimentin into an antigen in rheumatoid arthritis [54], but also into an antigen for anti-tumor immunity [57].

From all the above, it can be inferred that vimentin species present at the cell surface or in the extracellular medium can be structurally and functionally diverse. Indeed, the structural organization of extracellular vimentin and/or the concurrent PTMs could potentially influence its actions. Based on epitope recognition by a variety of antibodies, it has been reported that the tail domain is accessible in activated platelets [45] and on the surface of human cerebral microvascular endothelial cells [58]. Nevertheless, evidence from deletion analysis indicated that the head domain of vimentin could be involved in protein–protein interactions in the extracellular medium [44]. However, in our view, some caution needs to be exercised regarding results obtained with deletion mutants since the assembly, localization and/or interactions of constructs lacking the N-terminal or C-terminal domains could be compromised. In a recent study, Hwang and Ise have analyzed cell surface type III intermediate filament proteins and showed that they are present in multimeric complexes [59]. Moreover, they show that multimeric, but not filamentous forms, associate with lipid bilayers with high affinity, which could suggest that PTM-mediated disassembly of filamentous vimentin would be necessary for this association.

Surface-exposed or secreted vimentin can interact with several partners (Figure 1). In platelets, cell surface vimentin (CSV) has been involved in mediating adhesion at sites of injury by interaction with

Von Willebrandt Factor (VWF) [45], reportedly through the tail domain. Pharmacological disruption of this interaction, either with anti-vimentin antibodies or with a VWF fragment, exerted beneficial effects in experimental models of ischemic stroke [60]. Vimentin exposed on HUVEC can interact with soluble CD44, allegedly through the head domain [44], whereas the C-terminal domain has been postulated to mediate the interaction of soluble vimentin with insulin-like growth factor 1 receptor (IGF-1R) [61]. Vimentin can also interact with Dectin-1 [62] and with pathogen proteins, which will be considered in more detail below. Importantly, since some pathogen proteins are heavily glycosylated, this binding could be favored by the lectin-like properties of cell surface vimentin. Indeed, vimentin has the ability to engage N-AcGln either on proteins in cell debris or dying cells, or on artificial matrices/polymers. This interaction has been reported to occur through coil 2 of the rod domain (residues 288 to 406), and proposed to contribute to dying cell clearance [49,63,64].

In summary, extracellular vimentin, either exposed on the cell surface or secreted, can likely exist as multiple proteoforms that exert complex and conceivably double-edged actions through interactions with diverse receptors or targets, in a context-dependent manner. A deeper understanding of these processes will be key to understand vimentin implications in pathogenesis.

#### 4. Vimentin in Tissue Damage and Repair

Vimentin is both a player and a target in tissue damage and repair. Regarding its implications in infection, as it will be detailed below, pathogens and/or the associated damage can induce vimentin expression and/or surface exposure [65,66], which, in turn could hypothetically contribute to infection. Moreover, vimentin function is crucial for tissue repair, although its deregulation can lead to fibrosis [12,16]. Vimentin plays a critical role in wound healing. However, this role appears to be complex and depend on the specific tissue and time after injury. The implications of cellular vimentin in wound healing and cell migration have been the subject of several excellent reviews [2,67]. Nevertheless, the role of extracellular vimentin in tissue damage and repair is not completely characterized.

As mentioned above, vimentin is secreted by activated macrophages, helping to combat infection by acting as a proinflammatory factor, triggering the generation of oxidative metabolites and bacterial killing [14]. On the other hand, vimentin released from injured cells can bind to the surface of mesenchymal leader cells, mediating their transition to a myofibroblast phenotype and supporting wound closure [68]. In spinal cord injury, vimentin secreted by astrocytes at the injured area has been proposed to act as a neurotrophic factor, enhancing axonal growth and motor function recovery [69]. Moreover, recombinant vimentin treatment reduced acute lung injury induced by lipopolysaccharide (LPS), due, at least in part, to its binding to P-selectin, which precludes interaction with P-selectin glycoprotein ligand (PSGL-1) and the consequent interaction of leukocytes with the endothelium [70]. However, secreted vimentin can also play a pathogenic role. Levels of secreted vimentin as determined by ELISA are increased in the serum of patients with coronary artery disease, constituting an independent determinant of this condition [71]. In addition, recombinant vimentin promoted inflammatory changes in endothelial cells and macrophages, as well as inflammatory and atherogenic changes in *ApoE*<sup>-/-</sup> mice [71].

In turn, cell surface vimentin has relevant consequences on tissue damage and repair through interactions with some of its partners. During infection of monocytes with *Mycobacterium tuberculosis*, vimentin is exposed on the cell surface and acts as a ligand for NKp46 receptor on natural killer cells, inducing their activation and lysis of infected cells [72]. Moreover, monocytes are able to bind to exposed vimentin due to complement factors, IgG and fibrinogen [73–75]. A potential pro-repair role for surface vimentin is also supported by its recruitment to the cell surface, after phosphorylation and disassembly of the intermediate filaments, in order to bind GlcNAc-modified proteins [49] (Figure 1), and facilitate the engulfment of apoptotic cells by macrophages and mesenchymal cells [76]. Soluble and full-length CD44, the receptor of the anti-inflammatory molecule hyaluronan, bind cell surface vimentin (Figure 1) through their hyaluronan binding domains, although a mutant unable to bind hyaluronan could still bind vimentin [44]. Further studies are necessary to evaluate the effect of

vimentin binding to CD44, an important receptor in lung resolution of inflammation and repair [77]. However, cell surface vimentin also has pro-coagulant properties, interacting with VWF to promote platelet adhesion [45] or VWF string formation [60]. Activated platelets exposing vimentin on their surface bind to vitronectin and active Plasminogen Activator Inhibitor 1 (PAI-1) complexes [78] (Figure 1). Vimentin stabilizes these complexes, which can inhibit epithelial repair [79] and exacerbate pulmonary fibrosis [80,81].

Vimentin is differentially expressed in proinflammatory M1 and pro-repair M2 macrophages, presenting higher levels in M2 macrophages [82], which are able to accelerate lung repair [83,84]. In the same sense, vimentin is necessary for the correct repair and remodeling of alveolar epithelial cells [85], where it is important for cell motility in repair and regeneration [67]. Thus, vimentin has important implications in lung injury and repair. Lung tissues are damaged by pathogenic infection such as viral replication inside cells, but are also damaged by the inflammatory immune response, which can be exacerbated.

Therefore, many of the documented actions of vimentin imply a necessary or beneficial role in tissue repair. Nevertheless, vimentin can also participate in pathogenic mechanisms in situations of deregulation of the immune or fibrotic responses.

## 5. Vimentin in Immune Responses

Vimentin plays a role in many key processes of the immune response. The establishment of an efficient immune response to viral or bacterial infection is critical for viral clearance and recovery. However, some viral infections are characterized by exaggerated inflammation that can cause severe immunopathology, such as acute lung injury caused by SARS-CoV-2 [86] and influenza virus infections [87]. Infection is sensed in host cells by a variety of pattern recognition receptors (PRRs), which leads to expression of cytokines and other mediators. Interestingly, vimentin has been described as a ligand for some PRRs. The nucleotide-binding oligomerization domain-containing protein 2 (NOD2) interacts with vimentin, and this interaction is required for subsequent NF- $\kappa$ B activation [88]. In addition, vimentin is required for assembly and activation of the NLRP3 inflammasome, which mediates the induction of pro-inflammatory cytokines associated with acute lung injury in bacterial and viral infections [12]. In turn, stimulation of the retinoic acid-inducible gene I (RIG-I), an important cytosolic PRR that detects viral RNA and mediates induction of type I and III interferon expression, leads to increased expression of vimentin [89]. Extracellular receptors also play important roles in the innate immune response to viral infections [90,91]. In this context, it has been shown that extracellular vimentin is a ligand for the PRR Dectin-1 [62], a M2 macrophage marker [83,92], the engagement of which triggers reactive oxygen species (ROS) production. Extracellular vimentin also switches the cytokine profile of LPS-activated dendritic cells by decreasing secretion of pro-inflammatory cytokines (IL-6, IL-12) and increasing IL-10 secretion, an anti-inflammatory cytokine, thereby reducing Th1 differentiation of naïve T cells [93]. Importantly, vimentin has been identified as a metabolic and functional controller of the activity of regulatory T-cells, which are critical for immune homeostasis and prevention of autoimmune and inflammatory disorders [94]. Thus, vimentin disruption enhances regulatory T-cell potency, improving their ability to suppress graft-versus-host disease [94]. A significant role was also shown for vimentin in diapedesis, i.e., crossing of leukocytes through the endothelium, where both lymphocytes and endothelial cells rely on vimentin for correct expression and distribution of adhesion-related molecules such as ICAM-1, VCAM-1 or integrin-beta1 [95]. Studies in B cells also show vimentin involvement upon antigen stimulation, for intracellular vesicles containing antigen or lysosomal associated membrane protein 1 (LAMP1) showed aberrant distribution in vimentin-deficient B cells, which are less able to present antigens, delaying *in vivo* antibody responses [96].

Interestingly, vimentin, usually modified by citrullination, and likely by other modifications such as oxidation and/or proteolysis, becomes an autoantigen in autoimmune disease. Indeed, these modifications could lead to the exposure of epitopes not usually accessible to the immune system and trigger an immune reaction. Anti-vimentin autoantibodies (AVA) have been detected in

situations associated with tissue damage, such as chronic hemodialysis, and in transplant rejection [97] (for a recent review, see [98]). Moreover, they have a prognostic character in several pathological conditions. Therefore, the process of vimentin recognition and activation of the immune system has become an important drug target, and efforts are being devoted to develop strategies to block this process.

There are many autoimmune diseases that involve the presence of autoantibodies against vimentin. Particularly, rheumatoid arthritis (RA) patients produce antibodies against citrullinated proteins, including vimentin [19], that can be used for diagnosis. AVA can be found in immune complexes purified from synovial fluid [99] and in RA patients' lungs [100]. Furthermore, recent data point to the role of vimentin in RA synovial fibroblasts as mediators of autoimmunity, since autophagy in these cells induces vimentin citrullination and interaction with MHC-II [55]. Circulating citrullinated vimentin is associated with disease progression and hence is also a potential biomarker of disease in ankylosing spondyloarthritis [101]. Similarly, citrullinated and matrix metalloproteinase-degraded vimentin serum levels showed high diagnostic power to differentiate Crohn's disease from ulcerative colitis [102], and as an indicator of the response to treatment [103].

Systemic lupus erythematosus patients with kidney damage in the form of severe tubulointerstitial inflammation present high serum AVA levels. At these renal inflammatory loci, activated macrophages secrete more surface vimentin, leading to more AVA that can activate the complement system and ultimately cause tissue damage and fibrosis [104]. Recently, AVA were compared to other autoantibodies in lupus and found to be specific prognostic factors of worse response to treatment, particularly IgG AVAs [105]. Additionally, recent studies found serum antibodies against carbamoylated vimentin in lupus, an example of yet another PTM that can enhance its immunogenicity [106].

Anti-vimentin antibodies have been found in bronchoalveolar lavage fluid (BALF) from both healthy subjects and sarcoidosis patients. Nevertheless, the titers were higher in patients and the predominant reactivity was directed against the tail domain of vimentin, whereas antibodies in healthy controls were predominantly directed against the N-terminal (head) domain. Moreover, high anti-vimentin antibody levels were associated with reduced lung function. Interestingly, patients expressing HLA-DRB1\*03 had a more pronounced enrichment of C-terminus-detecting AVA [107]. This HLA allotype is shared with many systemic lupus erythematosus patients, suggesting that tertiary lymphoid structures using vimentin as an antigen could appear in several chronic inflammatory diseases. In another inflammatory lung disease, namely, idiopathic pulmonary fibrosis, high circulating IgG AVA levels correlate with poor prognosis, though neither HLA allotypes nor in situ humoral immune reactions were studied in depth [108]. AVAs are also found in anti-phospholipid syndrome, where vimentin forms complexes with cardiolipin against which autoantibodies form [109].

In addition to recognition of PTM-altered vimentin, molecular mimicry-dependent cross-reactivity has been related to the development of autoimmune disease as a consequence of bacterial or viral infections [110]. In these processes, antibodies produced against pathogen antigens also recognize self-components, due to epitope similarity. For instance, antibodies recognizing streptococcal M proteins or specific proteins from herpes, measles or vaccinia viruses have been shown to recognize vimentin [111–113].

It is clear from the examples above that vimentin can act as a potent antigen, giving rise to autoantibodies and even in situ humoral responses (i.e., tertiary lymphoid structures). Importantly, serum vimentin levels are increased in patients with sepsis and septic shock, regulating inflammatory responses and lymphocyte apoptosis [114], which underlines its importance in immune involvement during infectious processes, as well.

## 6. Vimentin in Host-Pathogen Interactions

The involvement of vimentin in the response to pathogens presents many different features. On one hand, vimentin is an important element of the immune response and is necessary for optimal signaling in immune cells. Moreover, as stated above, vimentin acts as a ligand for pattern recognition

receptors, such as Dectin-1 and the nod-like receptor protein NLRP3 inflammasome, and elicits a defense response [12,22]. However, vimentin present at the cell surface has been known for some time to act as a receptor or co-receptor for pathogens, including bacteria and viruses. Additionally, intracellular vimentin can be hijacked by pathogens leading to impairment or subversion of its functions, which then contribute to the formation of intracellular pathogen reservoirs or facilitate pathogen replication [115–117].

The cell or tissue distribution of vimentin expression is relevant in this context. Although endothelial and immune cells express vimentin, not all epithelial cell types, which are the target cell type in respiratory infections, for instance, express this protein, unless they have suffered injury, epithelial-mesenchymal transition or acquire an activated state [85]. Remarkably, certain lung infections, e.g., mycobacterial infections, are more frequent in patients whose lungs may be already damaged due to previous diseases, thus, likely expressing high vimentin levels as part of the process of tissue damage and repair [118]. Nevertheless, some epithelia express vimentin focally [119]. In particular, certain lung epithelial cells, including columnar and basal cells, can also express vimentin (see below) [120,121]. Numerous studies on pathogen invasion have been carried out in vitro using cancer epithelial or fibroblast-like cell lines, which express vimentin, like the Vero cell line that is frequently used in the study of viral infections. Although they may not represent ideal models, these studies have evidenced that modulation of vimentin levels by various strategies induces parallel changes in pathogen invasion [119]. In addition, certain strategies, including anti-vimentin antibodies or soluble vimentin, have been reported to reduce binding of bacterial microaggregates or viral particles to carcinoma cells [20,118].

### 6.1. Bacterial Infections

Vimentin has been involved in bacterial binding to several cell types, including endothelial, epithelial and immune cells (reviewed in [22]). Interestingly, vimentin has been reported to mediate the effect of matrix stiffness on invasion of human microvascular endothelial cells (HMEC-1) by *Listeria monocytogenes*. In this in vitro model, vimentin was identified as a candidate surface receptor. Reducing the availability of surface vimentin, either with anti-vimentin antibodies, siRNA or chemical treatment to induce network disruption attenuated cellular infection [122]. Consistent with these findings, vimentin knockout mice have shown decreased colonization of the brain by *Listeria monocytogenes* [123], or by *E. coli* K1 invasion, thus evidencing vimentin-dependent mechanisms in bacterial meningitis [124]. *Streptococcus agalactiae* induces meningitis in newborns. Bacterial adherence to cerebral microvascular endothelial cells is facilitated by the adhesin BspC. Importantly, BspC interacts with vimentin, and vimentin-null mice are protected from *S. agalactiae* infection, suggesting that the vimentin–BspC interaction is important in the pathogenesis of meningitis [58].

Infectious agents can also modulate vimentin to facilitate infection. Agents like *Chlamydia trachomatis* or *Salmonella typhimurium* can recruit and/or remodel vimentin filaments to stabilize bacterial inclusions or to position microcolonies at a cellular location favorable for their replication [115,125]. Hijacking of vimentin functions could be mediated by pathogen-induced PTMs. Indeed, the streptococcal enzyme SpyA ADP-ribosylates vimentin at sites located in the head domain, altering its assembly [126], whereas the *Toxoplasma gondii* kinase ROP18 phosphorylates vimentin and affects its distribution [116]. Interestingly, *Chlamydia* induces O-glycosylation of vimentin to rearrange filaments for its own protection, and cells lacking the machinery to carry out this modification become resistant to *Chlamydia* infection [36].


The domains of vimentin involved in interaction with bacterial proteins appear to be variable. The *E. Coli* K1 virulence factor/invasion protein IbeA was shown to preferentially bind to a GST fusion construct of the head domain of vimentin in an overlay assay [43]. Moreover, vimentin has been reported to interact with and cooperate in the cellular uptake of C3 toxin from *Clostridium botulinum*, and this interaction appears to be mediated by the vimentin rod domain, as suggested by gel-overlay assays [127]. Interestingly, an integrin binding motif in the toxin appears to be important for binding



to intact cells and to recombinant vimentin [128]. Nevertheless, further structural studies are required to characterize the interactions of vimentin with bacterial pathogens.

## 6.2. Viral Infections

Vimentin has been shown to play important roles during infection by viruses from multiple families with different types of genomes (DNA, single-stranded RNA, double-stranded RNA, etc.) and replication cycles. Remarkably, there is also great diversity in the viral cycle stages that are impacted by vimentin, with reports ranging from early stages such as binding/entry, fusion or release of virus genome to the cytosol, or later stages such as replication or assembly (Figure 2).



**Figure 2.** Diverse roles of vimentin during viral infections. (A) Vimentin has been proposed to act as a receptor or co-receptor for multiple viruses, e.g., severe acute respiratory syndrome-related coronavirus (SARS-CoV) [66]. (B) Extracellular vimentin (surface and soluble) restricts infection by HPV [129]. Intracellular vimentin blocks influenza A virus (IAV) infection at the fusion step [130] (C) and translocation of IAV viral ribonucleoproteins (vRNPs) to the nucleus [131] (D). (E) Vimentin interacts with dengue virus (DENV) NS4A at the replication complex and interferes with RNA replication [132]. (F) Vimentin has a role in assembly of some viruses (e.g., vaccinia virus), by supporting the formation of viral factories [133]. This illustration was created with BioRender (<https://biorender.com>).

The SARS-CoV that caused the 2002 outbreak in China, as well as the novel SARS-CoV2 causing COVID-19, bind to their cellular receptors through their Spike (S) protein. The S proteins of these two viruses present approximately 76% amino acid identity and 87% homology (BLAST of PDB code 6VXX, SARS-CoV-2 spike glycoprotein, and PDB code 5WRG, SARS-CoV spike glycoprotein). Angiotensin converting enzyme (ACE) 2 was identified as a cellular receptor for the entry of SARS-CoV [134]. Importantly, ACE2 is also the receptor for SARS-CoV2 [135]. In addition, both viruses employ the cellular transmembrane serine protease TMPRSS2 for S protein priming [135,136], eliciting proteolytic cleavage of S after receptor binding. This cleavage leads to conformational changes in S trimers that allow for subsequent fusion of the cellular and viral membranes and facilitates virus entry [137]. In the case of SARS-CoV, there is not a strict association between ACE2 expression and entry, indicating that there might be other cellular factors important in the entry process. In this regard, a study reported an important role for vimentin in SARS-CoV virus entry through interaction with its S protein [66] (Figure 2A). Interestingly, expression of extracellular vimentin was upregulated after this interaction. It is important to note that this study was performed using the cell line Vero E6, and therefore these results remain to be confirmed in relevant human primary cells. Notably, analysis of lung samples from SARS patients has shown infection of several cell types, including pneumocytes, but also immune

and endothelial cells and fibroblasts [138]. Infection of primary lung fibroblasts was also occasionally observed in an in vitro model [139]. Although interaction of vimentin with SARS-CoV2 is yet to be evaluated, a recently reported interaction map including all proteins from this virus identified potential interactions between vimentin and several viral proteins, including S protein [140]. In addition, several recent single cell RNA sequencing studies have shown that, besides pneumocytes, expression of SARS-CoV-2 entry factors, ACE2 and TMPRSS2, is particularly high in nasal epithelial goblet secretory cells and ciliated cells [141,142], in which early immunohistological studies had shown the presence of vimentin [143]. Moreover, SARS-CoV-2 infection of endothelial cells, known to express ACE2 and TMPRSS2 [144,145], has been confirmed recently [146]. However, differences in antigenicity and affinity binding to ACE2 between the S proteins from SARS-CoV and SARS-CoV-2 have been identified [147]. Therefore, further research at the protein level is needed to understand a possible role for vimentin as a receptor or co-receptor for both SARS-CoV and SARS-CoV-2.

A role for vimentin in binding and entry has been also suggested in the case of dengue virus (DENV) infections. Specifically, vimentin's rod domain has been shown to interact with the envelope protein of the virus in endothelial cells and promote virus absorption and subsequent infection [148]. A different report showed that enterovirus 71 also interacts with vimentin at the surface of the cell, but in this case the interaction occurs between its N-terminal portion and the most external viral protein, VP1 [20]. Additional reports have shown involvement of extracellular vimentin in virus attachment and entry for Japanese encephalitis virus [149,150], porcine reproductive and respiratory syndrome virus [151], cowpea mosaic virus [152] and Chandipura virus [153]. Interestingly, binding of viral particles to vimentin at the surface of host cells had an opposite effect in the case of human papillomavirus (HPV) 16 pseudovirions [129]. Schafer et al. reported that both surface-exposed and soluble extracellular vimentin could act as a restriction factor, probably by interfering with the interaction of the virus with the attachment receptor either through direct contact or steric hindrance, limiting internalization of the virus into epithelial cells (Figure 2B).

In the case of influenza A virus (IAV), it has been shown that vimentin is necessary for the release of viral ribonucleoproteins (vRNPs) to the cytoplasm through alteration of lysosomal trafficking during entry (Figure 2C). This effect seems to be associated with impaired acidification of early endosomes in cells lacking vimentin, which is necessary for membrane fusion during early stages of infection, resulting in defective release of vRNPs to the cytoplasm [130]. Indeed, vimentin is involved in promoting an adequate distribution and function of vesicular structures along the endolysosomal pathway [5,6]. In addition, vimentin has been found to interact with the PB2 unit of the IAV polymerase [131]. This interaction occurs in the perinuclear region of the cell and results in reduced translocation of vRNPs to the nucleus (Figure 2D), where IAV genome replication takes place, as well as decreased polymerase activity. Therefore, in this case vimentin acts as a restriction factor of viral replication. Interestingly, IAV infection induces upregulation of vimentin, but also evades its antiviral function by inducing expression of miRNA-1290, which targets vimentin mRNA for degradation [131].

During DENV infection, the N-terminal region of vimentin has been shown to interact with non-structural (NS) protein 4A, a hydrophobic protein that localizes to the endoplasmic reticulum with an important role in replication. Specifically, vimentin interacts with the N-terminal cytosolic portion of NS4A in the replication complexes in the endoplasmic reticulum (Figure 2E). In this work, they also found that vimentin is reorganized during infection, which was critical for the formation of the replication complexes [132]. A similar vimentin rearrangement has been reported during Human Enterovirus Group B infection [154]. Vimentin expression in this case was shown to be important for synthesis of non-structural viral proteins, and inhibition of vimentin lead to alteration of pro-apoptotic functions of those proteins, as well as prolonged cell survival [154]. In the case of infection by foot-and-mouth disease virus, vimentin interacts with non-structural protein 3A and exerts complex effects in viral replication and yield [155].

Intracellular vimentin has also been shown to play a role during vaccinia virus infection, where vimentin filaments concentrate around foci of active viral replication in the cell, known as viral factories

(Figure 2F), suggesting that they might have a part in virus assembly in this context [133]. A similar phenomenon has been reported for African swine fever virus infection, which initiated vimentin rearrangement to form a cage surrounding viral factories [156]. In this work, they found that vimentin N-terminus is phosphorylated after DNA-replication begins, which might be involved in the formation of these cage-like structures.

Additional studies have shown relevant roles for vimentin during viral infections. Vimentin has been found to interact with hepatitis C virus (HCV) core protein, which regulates its expression, impacting virus replication [157]. Vimentin is also important for efficient infection by HIV [158,159], through mechanisms that are not yet well understood. Interestingly, DeBoer et al. [158] also found that abundance of vimentin is increased in the cytoplasmic and membrane fractions in infected cell cultures. Conversely, vimentin expression has been observed to be negatively affected by virus infection in some cases. For instance, vimentin is a substrate for several viral proteases [40,160]. Infection by the Moloney mouse sarcoma virus was also found to induce vimentin cleavage resulting in a fragment lacking all or part of the C-terminal tail, as mentioned above [39].

In addition to the modulation of vimentin expression and PTMs by viruses, vimentin will also respond to host factors generated during the immune response. Indeed, vimentin expression can be regulated by proinflammatory cytokines, as well as by Type I and II interferons [161,162].

Therefore, vimentin has been shown to have important and diverse implications during virus–host interactions at the cellular level in myriad ways. The versatile nature of vimentin in terms of cellular localization, conformational arrangements and as a target for different PTMs has a critical role in these interactions. It should be noted that besides vimentin, other intermediate filament proteins can be involved in interaction with viruses, either because they participate in their entry or because they are hijacked by the virus to promote its replication cycle. Although they are not the topic of this article, information on their involvement in the pathogenesis of viral infections can be found in several review articles [163,164].

## 7. Strategies to Modulate Vimentin Function: Focus on Extracellular Vimentin-Pathogen Interactions

Given the importance of vimentin as a drug target in several diseases, and in particular its role in viral and bacterial infections, multiple strategies can be devised to interfere with its functions.

A disruption of cytoplasmic vimentin can be achieved by various means including interfering with its expression and/or distribution [165]. In addition, the functions of extracellular vimentin, either soluble or exposed on the cell surface, can be targeted by blocking antibodies or decoy peptides, as well as interfering with modifications and/or trafficking pathways leading to its exposure or release. Table 1 summarizes some of the strategies and active principles employed to target vimentin, or reported to affect its function, some of which will be discussed below. In addition, several recent reviews have considered the role of vimentin as a drug target [10,166].

### 7.1. Anti-Vimentin Antibodies

As detailed above, AVAs are generated in numerous inflammatory diseases. Although in most cases they appear to play a pathogenic role, in some cases they could elicit protective effects. Indeed, both endogenously generated and manufactured anti-vimentin antibodies have been used as potential therapeutic tools, above all in cancer. In fact, antibodies against extracellular vimentin have been envisaged as anti-tumoral agents, given the important implication of vimentin in epithelial-mesenchymal transition and cell migration [167]. In particular, an antibody against cell surface vimentin, known as 86C, has been reported to bind to and cause internalization of vimentin in glioblastoma multiforme tumor cells, resulting in loss of viability, apparently mediated by increased caspase 3 activity. Moreover, beneficial effects were obtained *in vivo* consisting in the inhibition of tumor progression [168].

**Table 1.** Agents/Strategies affecting vimentin function.

Macromolecules	Clinical Use	Putative Effect	Specificity for Vimentin	References
Expression vectors, wt and mutants/fragments		Mimic/inhibit	Very high	[6]
siRNAs		Inhibit expression	High	[20,129]
Recombinant vimentin and fragments		Mimic/compete vimentin release or exposure	High	[44,66]
Soluble CD44		Compete for vimentin binding	High	[44]
Pritumumab (anti-vimentin mAb)	Clinic, Phase II	Membrane vimentin binding	Very high	[169,170]
SC5 anti-vimentin mAb		Membrane vimentin binding	Very high	[171]
Anti-Cell surface vimentin (CSV) 86C mAb		Membrane vimentin binding and internalization	Very high	[168]
Anti-citrullinated Vimentin antibodies	Diagnostic	Biomarker	Very high	[19]
Hyaluronic acid (CTX-100)	Phase II	Compete with vimentin for CD44	Moderate-Low	NCT00993707 *
PEGPH20 (Pegylated Hyaluronidase)	Phase I	Reduce hyaluronan levels	Moderate-Low	[172]
$\beta$ -glucans (Proglucamune)	Dietary supplement	Dectin-1 agonist	Low	[173,174]
Dectin-1 blocking antibodies		Block Dectin-1 signals	High	[62]
Small Molecules	Clinical Use	Putative Effect	Specificity for Vimentin	References
Withaferin A	Withania Somnifera extract (WSE; Sensoril®)	Reduce vimentin levels, binds region of C328, phosphorylation	Moderate	[16,175]
Ajoene	Garlic oil & pure studies	Disrupt vimentin network and functions, bind C328	Low	[176]
Epigallocatechin gallate	Dietary supplement trials	Inhibit vimentin phosphorylation	Low	[177–179]
Gambogic acid	Traditional Asian medicine	Vimentin cleavage	Low	[180–182]
Simvastatin	Clinic	Vimentin distribution; viral entry inhibition; anti-inflammatory	Low	[183] NCT04348695 *
Cantharidin	Phase I-IV	Vimentin distribution; antiviral	Low	[183]
Carvedilol	Phase I-IV	Vimentin distribution	Low	[183]
Ivermectin	Phase I-IV	Vimentin distribution; COVID-19 and Dengue treatment	Low	[183] NCT04343092 *

\* ClinicalTrials.gov ID.

In addition, the SC5 monoclonal antibody, raised against an NK leukemic cell line, selectively recognizes vimentin located at the extracellular side of the plasma membrane in activated T cells and in viable malignant Sézary syndrome lymphocytes [171]. This antibody has been found to inhibit anti-CD3-induced proliferation and cytokine secretion of peripheral blood T cells and cell clones [184]. Furthermore, certain anti-vimentin antibodies have been shown to disrupt interactions of extracellular vimentin with its endogenous receptors, such as VWF [45,60], which could have beneficial effects.

Interestingly, anti-vimentin antibodies can also disrupt vimentin interaction with pathogen proteins, including the SARS-CoV spike protein [66], and putatively the streptococcal adhesin BspC [58], ameliorating some of the pathogenic processes in which vimentin is involved [58,60]. Therefore, these agents could hold promise for their use as therapeutic agents. Importantly, a natural monoclonal human IgG1 kappa anti-vimentin antibody derived from B lymphocytes from a patient with cervical carcinoma is undergoing clinical trials against glioma [169], in which it has shown positive results [185]. Interestingly, testing of this antibody (Pritumumab) as a strategy against COVID-19 has recently begun.

## 7.2. Chemical Agents

Several compounds have been reported to alter the organization of the vimentin network. Early works pointed to acrylamide as an agent inducing selective vimentin disruption [186]. Nevertheless, alterations in microtubules and microfilaments are also apparent in cells treated with this agent [187]. Another compound,  $\beta$ ,  $\beta'$ -iminodipropionitrile was reported to reversibly disrupt the vimentin network by apparently inducing filament disassembly [188]. Nevertheless, this agent is a neurotoxin, which precludes its clinical use.

The endogenous lipid mediators known as cyclopentenone prostaglandins covalently modify vimentin, selectively targeting their single cysteine residue, and inducing a collapse of the network towards the nuclear periphery [189]. These agents and other electrophilic lipids also bind to multiple cellular targets, including the transcription factor NF- $\kappa$ B, which was suggested to be at the basis of their antitumoral and antiviral actions [190]. A withanolide natural product, withaferin A (WFA), was also reported to bind vimentin at the region surrounding C328, disrupting filaments in cells [191]. In addition, WFA decreased vimentin levels in several experimental systems, which could convey beneficial effects in certain pathological conditions. However, this drug also poses specificity issues, since recent works indicate that it also alters the organization of a cysteine-deficient vimentin mutant and that it may target other cellular proteins [192,193]. Other natural products bind and disrupt the vimentin network, including the garlic compound ajoene, which binds to C328 inducing thiolation and alters vimentin-dependent functions [176], and the green tea polyphenol epigallocatechin gallate that binds vimentin and inhibits its phosphorylation in cells [177]. Given the important role of C328 in vimentin function, this residue can be postulated as an interesting site to perform virtual screenings for agents with modulatory properties.

In addition, several drug screening assays have been carried out, which have resulted in the identification of compounds disrupting vimentin organization [194]. In an image-based screening, several already approved drugs were found to alter vimentin, including the statins simvastatin and mevastatin [183]. Statins, widely used to lower blood cholesterol levels, pose an interesting case. Apparently, some, but not all statins disrupt vimentin distribution and folding both in cells and in vitro, and thus have the potential to interfere with cell surface vimentin [183]. Nevertheless, other statins including fluvastatin and lovastatin could interfere with vimentin through indirect mechanisms.

Statins have long been known to induce apoptosis in a variety of cancer cell lines, in part due to their ability to inhibit the isoprenylation of proteins needed for survival [195,196]. In this process, activation of caspases can result in vimentin cleavage, since this protein is a preferential caspase substrate [37]. Indeed, fluvastatin has been reported to decrease vimentin expression through caspase cleavage, selectively in breast cancer but not in normal cells [197]. Statins are well-characterized drugs. Remarkably, many COVID-19 patients are under chronic statin treatment and, given the cardiovascular complications of the disease, continuation, and even establishment of treatment with statins is being proposed [198]. Moreover, statins, in particular simvastatin, have been reported to interfere with the entry or replication of several viruses, including HIV or Zika virus [199,200], although their efficacy in patients needs further assessment. Interestingly, a clinical trial based on the combination of simvastatin and ruxolitinib for the treatment of COVID-19 has recently begun (EudraCT Number: 2020-001405-23; <https://www.clinicaltrialsregister.eu>). Other clinically used drugs or nutrients with capacity to disrupt vimentin could include daunorubicin, metamizole or even paracetamol. In addition,

other molecular entities found to alter vimentin distribution that have undergone clinical trials are cantharidin, carvediol and ivermectin [183]. Interestingly, ivermectin is an antiparasitic drug with broad antiviral activity *in vitro* that was recently reported to be highly effective against SARS-CoV-2 in cell culture models [201].

Certain chemicals may also induce vimentin cleavage by proteases that remain unidentified. This is the case of gambogic acid, a natural product with anti-inflammatory and anti-tumoral properties, which elicits vimentin cleavage in HeLa cells rendering products that are missing sequences before S51 and/or after R424 [180].

Most of the compounds listed above alter vimentin distribution. Nevertheless, whether they affect extracellular vimentin and its interactions requires further investigation. In principle, agents known to alter vimentin structure, such as simvastatin or cyclopentenone prostaglandins, could potentially affect extracellular vimentin. In addition, availability of divalent cations, including  $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$  and  $\text{Zn}^{2+}$  [6,202,203], can affect the state of vimentin oligomerization and its mechanical properties. However, whether they affect extracellular vimentin has not been studied.

### 7.3. Other Strategies

Vimentin or vimentin fragments have been used as decoys to inhibit the interaction of pathogens with cell surface proteins [20,204]. Nevertheless, further studies are needed since, as stated above, vimentin can also interact with Dectin-1 on macrophages promoting ROS production [62]. In the context of viral infections, recombinant vimentin has been shown to limit cell internalization of human papilloma virus 16 pseudovirions [129] and to reduce enterovirus 71 virus infection in cellular models [20]. However, multiple interactions may exist and these strategies need to be carefully considered. Vimentin can interact with PSGL-1, which has been recently shown to act as a restriction factor for several viruses [205]. Therefore, it would be necessary to ascertain whether binding to vimentin could help or compromise this function.

Experimental strategies to modulate vimentin expression have allowed establishing correlations between cellular vimentin levels and virus infectivity. Inhibition of vimentin expression by either siRNA [20,129], or shRNA [66] have been used in cellular models, although the results obtained point to cell- and virus-dependent effects of these strategies. Since RNA interference could affect surface and intracellular vimentin, the effects can be complex, and require careful assessment.

Vimentin has also been targeted by nucleic acid aptamers, above all in anti-cancer strategies. The DNA aptamer NAS-24 was delivered inside cells or employed in nanoparticles to induce apoptosis of cancer cells [206,207]. However, to the best of our knowledge, their use against cell surface vimentin has not been documented. In turn, an RNA aptamer, P15, has been found to selectively bind vimentin on the surface of cancer cells and reduce tumorigenic behavior of pancreatic cancer cells [208]. Therefore, nucleic acid aptamers could also be tested in vimentin–pathogen interactions.

Of note, as reflected in Table 1, the specificity of the agents or approaches reported to modulate vimentin is highly variable. Indeed, many of the listed drugs or natural products available for clinical use display a relatively low specificity for vimentin. Nevertheless, although a high specificity may be required for some applications, multi-target drugs can be convenient in certain conditions. Additionally, exploring the involvement of vimentin alterations in the effects of some of these drugs would be interesting to learn about the mechanisms of their beneficial or adverse effects.

## 8. Concluding Remarks and Perspectives

Although considered at first just a building block for intermediate filaments that fulfills a scaffold function, vimentin is emerging as a versatile protein which can exist as a host of structurally and functionally diverse protein species, or proteoforms, differing in their PTMs, oligomeric state, location and interactions. Vimentin is involved in essential intracellular processes, including cell signaling, organelle positioning and function, and integration of cytoskeletal dynamics. In addition, vimentin present on the surface of cells can carry out a great variety of roles in cell–cell interactions,

wound healing, migration and activation of the immune system. Importantly, cell surface vimentin has been identified as a receptor or co-receptor for pathogens. Recently, the participation of vimentin as a cellular co-receptor for SARS-CoV has been reported. Moreover, the presence of vimentin in several cell types together with other proteins involved in viral entry, such as ACE2 or TMPRSS2, grants efforts devoted to elucidate its potential role in coronavirus infections. In the context of COVID-19, identification of new pharmacological targets to design combination therapies would be desirable. Targeting vimentin in the context of viral infections could offer additional therapeutic possibilities. Some of the substances targeting vimentin, although in some instances with limited selectivity, are already in clinical use or in clinical trials. Nevertheless, given the pleiotropic character of vimentin actions, further research will be needed to establish the potentially beneficial and deleterious effects of approaches involving anti-vimentin antibodies and/or vimentin fragments. Undoubtedly, structural and functional characterization of extracellular vimentin in its various forms will be necessary for its consideration as a therapeutic target. Moreover, knowledge of the cellular mechanisms leading to the generation, trafficking and membrane targeting or secretion of extracellular vimentin would be key to be able to modulate this process.

**Author Contributions:** I.R. prepared illustrations and wrote the manuscript. K.S. prepared the table and wrote the manuscript. C.L.O. wrote and edited the manuscript. D.P.-S. prepared illustrations, wrote the manuscript and coordinated the study. All authors have read and agreed to the published version of the manuscript.

**Funding:** Work in DPS laboratory is supported by Grants from Agencia Estatal de Investigación, MINECO/FEDER, Spain, RTI2018-097624-B-I00, Instituto de Salud Carlos III/FEDER, RETIC Aradyal RD16/0006/0021, and CSIC PTI Global Health (PIE 202020E223/CSIC-COVID-19-100). IR research is partially supported by the NIH/National Institute of Allergy and Infectious Diseases-funded centers PRIME (Program for Research on Immune Modeling and Experimentation, U19AI117873), and DHIPC (Dengue Human Immunology Project Consortium, 1U19AI118610).

**Acknowledgments:** Feedback from COST Action CA15214 “EuroCellNet” is gratefully acknowledged. A former version of this work has been posted in Preprints 2020, 2020050041 (doi:10.20944/preprints202005.0041.v1).

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## Abbreviations

ACE	angiotensin converting enzyme
AVA	anti-vimentin autoantibodies
BALF	bronchoalveolar lavage fluid
CHO	Chinese hamster ovary
CSV	cell surface vimentin
DENV	dengue virus
HCV	hepatitis C virus
HIV	human immunodeficiency virus
HMEC	human microvascular endothelial cells
HUVEC	human umbilical endothelial cells
IAV	influenza A virus
ICAM-1	intercellular adhesion molecule 1
IGF-1R	insulin-like growth factor receptor 1
LAMP1	lysosomal-associated membrane protein 1
LPS	bacterial lipopolysaccharide
mAB	monoclonal antibody
N-AcGln	N-acetylglucosamine
NRLP3	nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3
NS4A	non-structural protein 4A
PAI-1	plasminogen activator inhibitor 1

PSLG-1	P-selectin glycoprotein ligand 1
PTM	posttranslational modification
PRR	pattern recognition receptor
RA	rheumatoid arthritis
RIG-I	retinoic acid-inducible gene I
ROS	reactive oxygen species
SARS-CoV	severe acute respiratory syndrome-related coronavirus
TMPRSS2	transmembrane protease, serine 2
ULF	unit-length filament
VCAM-1	vascular cell adhesion molecule 1
vRNP	viral ribonucleoprotein
VWF	Von Willebrandt Factor
WFA	withaferin A

## References

- Gan, Z.; Ding, L.; Burckhardt, C.J.; Lowery, J.; Zaritsky, A.; Sitterley, K.; Mota, A.; Costigliola, N.; Starker, C.G.; Voytas, D.F.; et al. Vimentin Intermediate Filaments Template Microtubule Networks to Enhance Persistence in Cell Polarity and Directed Migration. *Cell Syst.* **2016**, *3*, 252–263 e258. [[CrossRef](#)] [[PubMed](#)]
- Battaglia, R.A.; Delic, S.; Herrmann, H.; Snider, N.T. Vimentin on the move: New developments in cell migration. *F1000Research* **2018**, *7*, 1796. [[CrossRef](#)]
- Etienne-Manneville, S. Cytoplasmic Intermediate Filaments in Cell Biology. *Annu. Rev. Cell Dev. Biol.* **2018**, *34*, 1–28. [[CrossRef](#)]
- Duarte, S.; Viedma-Poyatos, A.; Navarro-Carrasco, E.; Martinez, A.E.; Pajares, M.A.; Perez-Sala, D. Vimentin filaments interact with the actin cortex in mitosis allowing normal cell division. *Nat. Commun.* **2019**, *10*, 4200. [[CrossRef](#)] [[PubMed](#)]
- Styers, M.L.; Salazar, G.; Love, R.; Peden, A.A.; Kowalczyk, A.P.; Faundez, V. The endo-lysosomal sorting machinery interacts with the intermediate filament cytoskeleton. *Mol. Biol. Cell* **2004**, *15*, 5369–5382. [[CrossRef](#)] [[PubMed](#)]
- Pérez-Sala, D.; Oeste, C.L.; Martínez, A.E.; Garzón, B.; Carrasco, M.J.; Cañada, F.J. Vimentin filament organization and stress sensing depend on its single cysteine residue and zinc binding. *Nat. Commun.* **2015**, *6*, 7287. [[CrossRef](#)] [[PubMed](#)]
- Chernoivanenko, I.S.; Matveeva, E.A.; Gelfand, V.I.; Goldman, R.D.; Minin, A.A. Mitochondrial membrane potential is regulated by vimentin intermediate filaments. *FASEB J.* **2015**, *29*, 820–827. [[CrossRef](#)]
- Watabe, M.; Nakaki, T. Protein kinase CK2 regulates the formation and clearance of aggresomes in response to stress. *J. Cell Sci.* **2011**, *124*, 1519–1532. [[CrossRef](#)]
- Patteson, A.E.; Vahabikashi, A.; Pogoda, K.; Adam, S.A.; Mandal, K.; Kittisopikul, M.; Sivagurunathan, S.; Goldman, A.; Goldman, R.D.; Janmey, P.A. Vimentin protects cells against nuclear rupture and DNA damage during migration. *J. Cell Biol.* **2019**, *218*, 4079–4092. [[CrossRef](#)]
- Danielsson, F.; Peterson, M.K.; Caldeira Araujo, H.; Lautenschlager, F.; Gad, A.K.B. Vimentin Diversity in Health and Disease. *Cells* **2018**, *7*, 147. [[CrossRef](#)]
- Eckes, B.; Colucci-Guyon, E.; Smola, H.; Nodder, S.; Babinet, C.; Krieg, T.; Martin, P. Impaired wound healing in embryonic and adult mice lacking vimentin. *J. Cell Sci.* **2000**, *113 Pt. 13*, 2455–2462.
- Dos Santos, G.; Rogel, M.R.; Baker, M.A.; Troken, J.R.; Urich, D.; Morales-Nebreda, L.; Sennello, J.A.; Kutuzov, M.A.; Sitikov, A.; Davis, J.M.; et al. Vimentin regulates activation of the NLRP3 inflammasome. *Nat. Commun.* **2015**, *6*, 6574. [[CrossRef](#)] [[PubMed](#)]
- Haversen, L.; Sundelin, J.P.; Mardinoglu, A.; Rutberg, M.; Stahlman, M.; Wilhelmsson, U.; Hulthen, L.M.; Pekny, M.; Fogelstrand, P.; Bentzon, J.F.; et al. Vimentin deficiency in macrophages induces increased oxidative stress and vascular inflammation but attenuates atherosclerosis in mice. *Sci. Rep.* **2018**, *8*, 16973. [[CrossRef](#)] [[PubMed](#)]
- Mor-Vaknin, N.; Punturieri, A.; Sitwala, K.; Markovitz, D.M. Vimentin is secreted by activated macrophages. *Nat. Cell Biol.* **2003**, *5*, 59–63. [[CrossRef](#)] [[PubMed](#)]



15. Wang, Z.; Divanyan, A.; Jourdeuil, F.L.; Goldman, R.D.; Ridge, K.M.; Jourdeuil, D.; Lopez-Soler, R.I. Vimentin expression is required for the development of EMT-related renal fibrosis following unilateral ureteral obstruction in mice. *Am. J. Physiol. Ren. Physiol.* **2018**, *315*, F769–F780. [[CrossRef](#)] [[PubMed](#)]
16. Suroliya, R.; Li, F.J.; Wang, Z.; Li, H.; Dsouza, K.; Thomas, V.; Mirov, S.; Perez-Sala, D.; Athar, M.; Thannickal, V.J.; et al. Vimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury. *JCI Insight* **2019**, *4*. [[CrossRef](#)] [[PubMed](#)]
17. Liu, C.Y.; Lin, H.H.; Tang, M.J.; Wang, Y.K. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. *Oncotarget* **2015**, *6*, 15966–15983. [[CrossRef](#)]
18. Richardson, A.M.; Havel, L.S.; Koyen, A.E.; Konen, J.M.; Shupe, J.; Wiles, W.G.T.; Martin, W.D.; Grossniklaus, H.E.; Sica, G.; Gilbert-Ross, M.; et al. Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. *Clin. Cancer Res.* **2018**, *24*, 420–432. [[CrossRef](#)]
19. Vossenaar, E.R.; Despres, N.; Lapointe, E.; van der Heijden, A.; Lora, M.; Senshu, T.; van Venrooij, W.J.; Menard, H.A. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. *Arthritis Res.* **2004**, *6*, R142–R150. [[CrossRef](#)]
20. Du, N.; Cong, H.; Tian, H.; Zhang, H.; Zhang, W.; Song, L.; Tien, P. Cell surface vimentin is an attachment receptor for enterovirus 71. *J. Virol.* **2014**, *88*, 5816–5833. [[CrossRef](#)]
21. MUSAELYAN, A.; LAPIN, S.; NAZAROV, V.; TKACHENKO, O.; GILBURD, B.; MAZING, A.; MIKHAILOVA, L.; SHOENFELD, Y. Vimentin as antigenic target in autoimmunity: A comprehensive review. *Autoimmun. Rev.* **2018**, *17*, 926–934. [[CrossRef](#)] [[PubMed](#)]
22. Mak, T.N.; Bruggemann, H. Vimentin in Bacterial Infections. *Cells* **2016**, *5*, 18. [[CrossRef](#)]
23. Herrmann, H.; Aebi, U. Intermediate Filaments: Structure and Assembly. *Cold Spring Harb. Perspect. Biol.* **2016**, *8*, a018242. [[CrossRef](#)]
24. Strelkov, S.V.; Herrmann, H.; Geisler, N.; Wedig, T.; Zimbelmann, R.; Aebi, U.; Burkhard, P. Conserved segments 1A and 2B of the intermediate filament dimer: Their atomic structures and role in filament assembly. *EMBO J.* **2002**, *21*, 1255–1266. [[CrossRef](#)] [[PubMed](#)]
25. Chernyatina, A.A.; Nicolet, S.; Aebi, U.; Herrmann, H.; Strelkov, S.V. Atomic structure of the vimentin central alpha-helical domain and its implications for intermediate filament assembly. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 13620–13625. [[CrossRef](#)] [[PubMed](#)]
26. Sokolova, A.V.; Kreplak, L.; Wedig, T.; Mucke, N.; Svergun, D.I.; Herrmann, H.; Aebi, U.; Strelkov, S.V. Monitoring intermediate filament assembly by small-angle x-ray scattering reveals the molecular architecture of assembly intermediates. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 16206–16211. [[CrossRef](#)] [[PubMed](#)]
27. Kirmse, R.; Bouchet-Marquis, C.; Page, C.; Hoenger, A. Three-dimensional cryo-electron microscopy on intermediate filaments. *Methods Cell Biol.* **2010**, *96*, 565–589. [[CrossRef](#)]
28. Chernyatina, A.A.; Guzenko, D.; Strelkov, S.V. Intermediate filament structure: The bottom-up approach. *Curr. Opin. Cell Biol.* **2015**, *32*, 65–72. [[CrossRef](#)]
29. Kornreich, M.; Avinery, R.; Malka-Gibor, E.; Laser-Azogui, A.; Beck, R. Order and disorder in intermediate filament proteins. *FEBS Lett.* **2015**, *589*, 2464–2476. [[CrossRef](#)]
30. Eriksson, J.E.; He, T.; Trejo-Skalli, A.V.; Härmälä-Braskén, A.-S.; Hellman, J.; Chou, Y.-H.; Goldman, R.D. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. *J. Cell Sci.* **2004**, *117*, 919–932. [[CrossRef](#)] [[PubMed](#)]
31. Chang, L.; Goldman, R.D. Intermediate filaments mediate cytoskeletal crosstalk. *Nat. Rev. Mol. Cell Biol.* **2004**, *5*, 601–613. [[CrossRef](#)] [[PubMed](#)]
32. Snider, N.T.; Omary, M.B. Post-translational modifications of intermediate filament proteins: Mechanisms and functions. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 163–177. [[CrossRef](#)] [[PubMed](#)]
33. Viedma-Poyatos, A.; Pajares, M.A.; Pérez-Sala, D. Type III intermediate filaments as targets and effectors of electrophiles and oxidants. *Redox Biol.* **2020**, 101582. [[CrossRef](#)]
34. Chavez, J.; Chung, W.G.; Miranda, C.L.; Singhal, M.; Stevens, J.F.; Maier, C.S. Site-specific protein adducts of 4-hydroxy-2(E)-nonenal in human THP-1 monocytic cells: Protein carbonylation is diminished by ascorbic acid. *Chem. Res. Toxicol.* **2010**, *23*, 37–47. [[CrossRef](#)] [[PubMed](#)]
35. Mónico, A.; Duarte, S.; Pajares, M.A.; Pérez-Sala, D. Vimentin disruption by lipoxidation and electrophiles: Role of the cysteine residue and filament dynamics. *Redox Biol.* **2019**, *23*, 101098. [[CrossRef](#)]

36. Tarbet, H.J.; Dolat, L.; Smith, T.J.; Condon, B.M.; O'Brien, E.T., 3rd; Valdivia, R.H.; Boyce, M. Site-specific glycosylation regulates the form and function of the intermediate filament cytoskeleton. *eLife* **2018**, *7*, e31807. [[CrossRef](#)]
37. Byun, Y.; Chen, F.; Chang, R.; Trivedi, M.; Green, K.J.; Cryns, V.L. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. *Cell Death Differ.* **2001**, *8*, 443–450. [[CrossRef](#)]
38. Pan, L.; Zhang, P.; Hu, F.; Yan, R.; He, M.; Li, W.; Xu, J.; Xu, K. Hypotonic Stress Induces Fast, Reversible Degradation of the Vimentin Cytoskeleton via Intracellular Calcium Release. *Adv. Sci. (Weinh)* **2019**, *6*, 1900865. [[CrossRef](#)]
39. Singh, B.; Arlinghaus, R.B. Vimentin phosphorylation by p37mos protein kinase in vitro and generation of a 50-kDa cleavage product in v-mos-transformed cells. *Virology* **1989**, *173*, 144–156. [[CrossRef](#)]
40. Shoeman, R.L.; Honer, B.; Stoller, T.J.; Kesselmeier, C.; Miedel, M.C.; Traub, P.; Graves, M.C. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 6336–6340. [[CrossRef](#)]
41. Frescas, D.; Roux, C.M.; Aygun-Sunar, S.; Gleiberman, A.S.; Krasnov, P.; Kurnasov, O.V.; Strom, E.; Virtuoso, L.P.; Wrobel, M.; Osterman, A.L.; et al. Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E1668–E1677. [[CrossRef](#)] [[PubMed](#)]
42. Janciauskiene, S.; Tumpara, S.; Wiese, M.; Wrenger, S.; Vijayan, V.; Gueler, F.; Chen, R.; Madyaningrana, K.; Mahadeva, R.; Welte, T.; et al. Alpha1-antitrypsin binds hemin and prevents oxidative activation of human neutrophils: Putative pathophysiological significance. *J. Leukoc Biol.* **2017**, *102*, 1127–1141. [[CrossRef](#)] [[PubMed](#)]
43. Zou, Y.; He, L.; Huang, S.H. Identification of a surface protein on human brain microvascular endothelial cells as vimentin interacting with Escherichia coli invasion protein IbeA. *Biochem. Biophys. Res. Commun.* **2006**, *351*, 625–630. [[CrossRef](#)] [[PubMed](#)]
44. Pall, T.; Pink, A.; Kasak, L.; Turkina, M.; Anderson, W.; Valkna, A.; Kogerman, P. Soluble CD44 interacts with intermediate filament protein vimentin on endothelial cell surface. *PLoS ONE* **2011**, *6*, e29305. [[CrossRef](#)] [[PubMed](#)]
45. Da, Q.; Behymer, M.; Correa, J.I.; Vijayan, K.V.; Cruz, M.A. Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. *Blood* **2014**, *123*, 2715–2721. [[CrossRef](#)] [[PubMed](#)]
46. Xu, B.; deWaal, R.M.; Mor-Vaknin, N.; Hibbard, C.; Markovitz, D.M.; Kahn, M.L. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. *Mol. Cell Biol.* **2004**, *24*, 9198–9206. [[CrossRef](#)]
47. Kim, S.; Cho, W.; Kim, I.; Lee, S.H.; Oh, G.T.; Park, Y.M. Oxidized LDL induces vimentin secretion by macrophages and contributes to atherosclerotic inflammation. *J. Mol. Med.* **2020**. [[CrossRef](#)]
48. Avram, D.; Romijn, E.P.; Pap, E.H.; Heck, A.J.; Wirtz, K.W. Identification of proteins in activated human neutrophils susceptible to tyrosyl radical attack. A proteomic study using a tyrosylating fluorophore. *Proteomics* **2004**, *4*, 2397–2407. [[CrossRef](#)]
49. Komura, K.; Ise, H.; Akaike, T. Dynamic behaviors of vimentin induced by interaction with GlcNAc molecules. *Glycobiology* **2012**, *22*, 1741–1759. [[CrossRef](#)]
50. Laragione, T.; Gianazza, E.; Tonelli, R.; Bigini, P.; Mennini, T.; Casoni, F.; Massignan, T.; Bonetto, V.; Ghezzi, P. Regulation of redox-sensitive exofacial protein thiols in CHO cells. *Biol. Chem.* **2006**, *387*, 1371–1376. [[CrossRef](#)]
51. Checconi, P.; Salzano, S.; Bowler, L.; Mullen, L.; Mengozzi, M.; Hanschmann, E.M.; Lillig, C.H.; Sgarbanti, R.; Panella, S.; Nencioni, L.; et al. Redox proteomics of the inflammatory secretome identifies a common set of redoxins and other glutathionylated proteins released in inflammation, influenza virus infection and oxidative stress. *PLoS ONE* **2015**, *10*, e0127086. [[CrossRef](#)]
52. Gronwall, C.; Amara, K.; Hardt, U.; Krishnamurthy, A.; Steen, J.; Engstrom, M.; Sun, M.; Ytterberg, A.J.; Zubarev, R.A.; Scheel-Toellner, D.; et al. Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis. *J. Autoimmun.* **2017**, *84*, 29–45. [[CrossRef](#)] [[PubMed](#)]
53. Moisan, E.; Girard, D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. *J. Leukoc Biol.* **2006**, *79*, 489–498. [[CrossRef](#)] [[PubMed](#)]

54. Bang, H.; Egerer, K.; Gauliard, A.; Luthke, K.; Rudolph, P.E.; Fredenhagen, G.; Berg, W.; Feist, E.; Burmester, G.R. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. *Arthritis Rheum* **2007**, *56*, 2503–2511. [[CrossRef](#)] [[PubMed](#)]
55. Sugawara, E.; Kato, M.; Kudo, Y.; Lee, W.; Hisada, R.; Fujieda, Y.; Oku, K.; Bohgaki, T.; Amengual, O.; Yasuda, S.; et al. Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. *Autophagy* **2020**, *16*, 946–955. [[CrossRef](#)] [[PubMed](#)]
56. Gyorgy, B.; Toth, E.; Tarcsa, E.; Falus, A.; Buzas, E.I. Citrullination: A posttranslational modification in health and disease. *Int. J. Biochem. Cell Biol.* **2006**, *38*, 1662–1677. [[CrossRef](#)] [[PubMed](#)]
57. Brentville, V.A.; Metheringham, R.L.; Gunn, B.; Symonds, P.; Daniels, I.; Gijon, M.; Cook, K.; Xue, W.; Durrant, L.G. Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T cell-mediated antitumor immunity. *Cancer Res.* **2016**, *76*, 548–570. [[CrossRef](#)]
58. Deng, L.; Spencer, B.L.; Holmes, J.A.; Mu, R.; Rego, S.; Weston, T.A.; Hu, Y.; Sanches, G.F.; Yoon, S.; Park, N.; et al. The Group B Streptococcal surface antigen I/II protein, BspC, interacts with host vimentin to promote adherence to brain endothelium and inflammation during the pathogenesis of meningitis. *PLoS Pathog.* **2019**, *15*, e1007848. [[CrossRef](#)]
59. Hwang, B.; Ise, H. Multimeric conformation of type III intermediate filaments but not the filamentous conformation exhibits high affinity to lipid bilayers. *Genes Cells* **2020**, *25*, 413–426. [[CrossRef](#)]
60. Fasipe, T.A.; Hong, S.H.; Da, Q.; Valladolid, C.; Lahey, M.T.; Richards, L.M.; Dunn, A.K.; Cruz, M.A.; Marrelli, S.P. Extracellular Vimentin/VWF (von Willebrand Factor) Interaction Contributes to VWF String Formation and Stroke Pathology. *Stroke* **2018**, *49*, 2536–2540. [[CrossRef](#)]
61. Shigyo, M.; Kuboyama, T.; Sawai, Y.; Tada-Umezaki, M.; Tohda, C. Extracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth. *Sci. Rep.* **2015**, *5*, 12055. [[CrossRef](#)] [[PubMed](#)]
62. Thiagarajan, P.S.; Yakubenko, V.P.; Elson, D.H.; Yadav, S.P.; Willard, B.; Tan, C.D.; Rodriguez, E.R.; Febbraio, M.; Cathcart, M.K. Vimentin is an endogenous ligand for the pattern recognition receptor Dectin-1. *Cardiovasc. Res.* **2013**, *99*, 494–504. [[CrossRef](#)] [[PubMed](#)]
63. Ise, H.; Kobayashi, S.; Goto, M.; Sato, T.; Kawakubo, M.; Takahashi, M.; Ikeda, U.; Akaike, T. Vimentin and desmin possess GlcNAc-binding lectin-like properties on cell surfaces. *Glycobiology* **2010**, *20*, 843–864. [[CrossRef](#)] [[PubMed](#)]
64. Ise, H.; Matsunaga, K.; Shinohara, M.; Sakai, Y. Improved Isolation of Mesenchymal Stem Cells Based on Interactions between N-Acetylglucosamine-Bearing Polymers and Cell-Surface Vimentin. *Stem Cells Int.* **2019**, *2019*, 4341286. [[CrossRef](#)]
65. Bryant, A.E.; Bayer, C.R.; Huntington, J.D.; Stevens, D.L. Group A streptococcal myonecrosis: Increased vimentin expression after skeletal-muscle injury mediates the binding of *Streptococcus pyogenes*. *J. Infect. Dis.* **2006**, *193*, 1685–1692. [[CrossRef](#)]
66. Yu, Y.T.; Chien, S.C.; Chen, I.Y.; Lai, C.T.; Tsay, Y.G.; Chang, S.C.; Chang, M.F. Surface vimentin is critical for the cell entry of SARS-CoV. *J. Biomed. Sci.* **2016**, *23*, 14. [[CrossRef](#)]
67. Cheng, F.; Eriksson, J.E. Intermediate Filaments and the Regulation of Cell Motility during Regeneration and Wound Healing. *Cold Spring Harb. Perspect. Biol.* **2017**, *9*, a022046. [[CrossRef](#)]
68. Walker, J.L.; Bleaken, B.M.; Romisher, A.R.; Alnwibit, A.A.; Menko, A.S. In wound repair vimentin mediates the transition of mesenchymal leader cells to a myofibroblast phenotype. *Mol. Biol. Cell* **2018**, *29*, 1555–1570. [[CrossRef](#)]
69. Shigyo, M.; Tohda, C. Extracellular vimentin is a novel axonal growth facilitator for functional recovery in spinal cord-injured mice. *Sci. Rep.* **2016**, *6*, 28293. [[CrossRef](#)]
70. Lam, F.W.; Da, Q.; Guillory, B.; Cruz, M.A. Recombinant Human Vimentin Binds to P-Selectin and Blocks Neutrophil Capture and Rolling on Platelets and Endothelium. *J. Immunol.* **2018**, *200*, 1718–1726. [[CrossRef](#)]
71. Gong, D.H.; Dai, Y.; Chen, S.; Wang, X.Q.; Yan, X.X.; Shen, Y.; Liu, J.; Yang, Z.K.; Hu, J.; Yu, L.J.; et al. Secretory vimentin is associated with coronary artery disease in patients and induces atherosclerosis in ApoE(-/-) mice. *Int. J. Cardiol.* **2019**, *283*, 9–16. [[CrossRef](#)] [[PubMed](#)]
72. Garg, A.; Barnes, P.F.; Porgador, A.; Roy, S.; Wu, S.; Nanda, J.S.; Griffith, D.E.; Girard, W.M.; Rawal, N.; Shetty, S.; et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. *J. Immunol.* **2006**, *177*, 6192–6198. [[CrossRef](#)] [[PubMed](#)]
73. Linder, E.; Helin, H.; Chang, C.M.; Edgington, T.S. Complement-mediated binding of monocytes to intermediate filaments in vitro. *Am. J. Pathol.* **1983**, *112*, 267–277. [[PubMed](#)]

74. Linder, E. Binding of C1q and complement activation by vascular endothelium. *J. Immunol* **1981**, *126*, 648–658.
75. Hansson, G.K.; Starkebaum, G.A.; Benditt, E.P.; Schwartz, S.M. Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cells. *Proc. Natl. Acad. Sci. USA* **1984**, *81*, 3103–3107. [[CrossRef](#)]
76. Ise, H.; Goto, M.; Komura, K.; Akaike, T. Engulfment and clearance of apoptotic cells based on a GlcNAc-binding lectin-like property of surface vimentin. *Glycobiology* **2012**, *22*, 788–805. [[CrossRef](#)] [[PubMed](#)]
77. Teder, P.; Vandivier, R.W.; Jiang, D.; Liang, J.; Cohn, L.; Pure, E.; Henson, P.M.; Noble, P.W. Resolution of lung inflammation by CD44. *Science* **2002**, *296*, 155–158. [[CrossRef](#)]
78. Podor, T.J.; Singh, D.; Chindemi, P.; Foulon, D.M.; McKelvie, R.; Weitz, J.I.; Austin, R.; Boudreau, G.; Davies, R. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. *J. Biol. Chem.* **2002**, *277*, 7529–7539. [[CrossRef](#)]
79. Lazar, M.H.; Christensen, P.J.; Du, M.; Yu, B.; Subbotina, N.M.; Hanson, K.E.; Hansen, J.M.; White, E.S.; Simon, R.H.; Sisson, T.H. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. *Am. J. Respir. Cell Mol. Biol.* **2004**, *31*, 672–678. [[CrossRef](#)]
80. Courey, A.J.; Horowitz, J.C.; Kim, K.K.; Koh, T.J.; Novak, M.L.; Subbotina, N.; Warnock, M.; Xue, B.; Cunningham, A.K.; Lin, Y.; et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. *Blood* **2011**, *118*, 2313–2321. [[CrossRef](#)]
81. Schuliga, M.; Grainge, C.; Westall, G.; Knight, D. The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. *Int. J. Biochem. Cell Biol.* **2018**, *97*, 108–117. [[CrossRef](#)] [[PubMed](#)]
82. Reales-Calderon, J.A.; Aguilera-Montilla, N.; Corbi, A.L.; Molero, G.; Gil, C. Proteomic characterization of human proinflammatory M1 and anti-inflammatory M2 macrophages and their response to *Candida albicans*. *Proteomics* **2014**, *14*, 1503–1518. [[CrossRef](#)] [[PubMed](#)]
83. D'Alessio, F.R.; Craig, J.M.; Singer, B.D.; Files, D.C.; Mock, J.R.; Garibaldi, B.T.; Fallica, J.; Tripathi, A.; Mandke, P.; Gans, J.H.; et al. Enhanced resolution of experimental ARDS through IL-4-mediated lung macrophage reprogramming. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2016**, *310*, L733–L746. [[CrossRef](#)] [[PubMed](#)]
84. Gindele, J.A.; Mang, S.; Pairet, N.; Christ, I.; Gantner, F.; Schymeinsky, J.; Lamb, D.J. Opposing effects of in vitro differentiated macrophages sub-type on epithelial wound healing. *PLoS ONE* **2017**, *12*, e0184386. [[CrossRef](#)]
85. Rogel, M.R.; Soni, P.N.; Troken, J.R.; Sitikov, A.; Trejo, H.E.; Ridge, K.M. Vimentin is sufficient and required for wound repair and remodeling in alveolar epithelial cells. *FASEB J.* **2011**, *25*, 3873–3883. [[CrossRef](#)]
86. Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J. Clin. Investig.* **2020**, *130*, 2620–2629. [[CrossRef](#)]
87. Ramos, I.; Fernandez-Sesma, A. Modulating the Innate Immune Response to Influenza A Virus: Potential Therapeutic Use of Anti-Inflammatory Drugs. *Front. Immunol.* **2015**, *6*, 361. [[CrossRef](#)]
88. Stevens, C.; Henderson, P.; Nimmo, E.R.; Soares, D.C.; Dogan, B.; Simpson, K.W.; Barrett, J.C.; Wilson, D.C.; Satsangi, J. The intermediate filament protein, vimentin, is a regulator of NOD2 activity. *Gut* **2013**, *62*, 695–707. [[CrossRef](#)]
89. De Rivero Vaccari, J.P.; Minkiewicz, J.; Wang, X.; De Rivero Vaccari, J.C.; German, R.; Marcillo, A.E.; Dietrich, W.D.; Keane, R.W. Astroglial activation involves activation of retinoic acid-inducible gene-like signaling in the innate immune response after spinal cord injury. *Glia* **2012**, *60*, 414–421. [[CrossRef](#)]
90. Ramos, I.; Bernal-Rubio, D.; Durham, N.; Belicha-Villanueva, A.; Lowen, A.C.; Steel, J.; Fernandez-Sesma, A. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. *J. Virol.* **2011**, *85*, 4421–4431. [[CrossRef](#)]
91. Ramos, I.; Fernandez-Sesma, A. Cell receptors for influenza a viruses and the innate immune response. *Front. Microbiol.* **2012**, *3*, 117. [[CrossRef](#)] [[PubMed](#)]
92. Nandakumar, V.; Hebrink, D.; Jenson, P.; Kottom, T.; Limper, A.H. Differential Macrophage Polarization from *Pneumocystis* in Immunocompetent and Immunosuppressed Hosts: Potential Adjunctive Therapy during Pneumonia. *Infect. Immun.* **2017**, *85*. [[CrossRef](#)] [[PubMed](#)]
93. Yu, M.B.; Guerra, J.; Firek, A.; Langridge, W.H.R. Extracellular vimentin modulates human dendritic cell activation. *Mol. Immunol.* **2018**, *104*, 37–46. [[CrossRef](#)] [[PubMed](#)]

94. McDonald-Hyman, C.; Muller, J.T.; Loschi, M.; Thangavelu, G.; Saha, A.; Kumari, S.; Reichenbach, D.K.; Smith, M.J.; Zhang, G.; Koehn, B.H.; et al. The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. *J. Clin. Investig.* **2018**, *128*, 4604–4621. [[CrossRef](#)] [[PubMed](#)]
95. Nieminen, M.; Henttinen, T.; Merinen, M.; Marttila-Ichihara, F.; Eriksson, J.E.; Jalkanen, S. Vimentin function in lymphocyte adhesion and transcellular migration. *Nat. Cell Biol.* **2006**, *8*, 156–162. [[CrossRef](#)]
96. Tsui, C.; Maldonado, P.; Montaner, B.; Borroto, A.; Alarcon, B.; Bruckbauer, A.; Martinez-Martin, N.; Batista, F.D. Dynamic reorganisation of intermediate filaments coordinates early B-cell activation. *Life Sci. Alliance* **2018**, *1*, e201800060. [[CrossRef](#)]
97. Mayet, W.J.; Wandel, E.; Hermann, E.; Dumann, H.; Kohler, H. Antibodies to cytoskeletal components in patients undergoing long-term hemodialysis detected by a sensitive enzyme-linked immunosorbent assay (ELISA). *Clin. Nephrol.* **1990**, *33*, 272–278.
98. Divanyan, T.; Acosta, E.; Patel, D.; Constantino, D.; Lopez-Soler, R.I. Anti-vimentin antibodies in transplant and disease. *Hum. Immunol.* **2019**, *80*, 602–607. [[CrossRef](#)]
99. Tilleman, K.; Van Steendam, K.; Cantaert, T.; De Keyser, F.; Elewaut, D.; Deforce, D. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. *Rheumatology* **2008**, *47*, 597–604. [[CrossRef](#)]
100. Ytterberg, A.J.; Joshua, V.; Reynisdottir, G.; Tarasova, N.K.; Rutishauser, D.; Ossipova, E.; Haj Hensvold, A.; Eklund, A.; Skold, C.M.; Grunewald, J.; et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: Identification and validation. *Ann. Rheum. Dis.* **2015**, *74*, 1772–1777. [[CrossRef](#)]
101. Bay-Jensen, A.C.; Karsdal, M.A.; Vassiliadis, E.; Wichuk, S.; Marcher-Mikkelsen, K.; Lories, R.; Christiansen, C.; Maksymowych, W.P. Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. *Arthritis Rheum* **2013**, *65*, 972–980. [[CrossRef](#)] [[PubMed](#)]
102. Mortensen, J.H.; Godskesen, L.E.; Jensen, M.D.; Van Haaften, W.T.; Klinge, L.G.; Olinga, P.; Dijkstra, G.; Kjeldsen, J.; Karsdal, M.A.; Bay-Jensen, A.C.; et al. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn’s Disease from Ulcerative Colitis. *J. Crohn’s Colitis* **2015**, *9*, 863–872. [[CrossRef](#)] [[PubMed](#)]
103. Mortensen, J.H.; van Haaften, W.T.; Karsdal, M.A.; Bay-Jensen, A.C.; Olinga, P.; Gronbaek, H.; Hvas, C.L.; Manon-Jensen, T.; Dijkstra, G.; Dige, A. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFalpha Treatment in Crohn’s Disease. *J. Clin. Gastroenterol.* **2020**. [[CrossRef](#)] [[PubMed](#)]
104. Kinloch, A.J.; Chang, A.; Ko, K.; Henry Dunand, C.J.; Henderson, S.; Maienschein-Cline, M.; Kaverina, N.; Rovin, B.H.; Salgado Ferrer, M.; Wolfgeher, D.; et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. *Arthritis Rheumatol.* **2014**, *66*, 3359–3370. [[CrossRef](#)]
105. Kinloch, A.J.; Cascino, M.D.; Dai, J.; Bermea, R.S.; Ko, K.; Vesselits, M.; Dragone, L.L.; Mor Vaknin, N.; Legendre, M.; Markovitz, D.M.; et al. Anti-vimentin antibodies: A unique antibody class associated with therapy-resistant lupus nephritis. *Lupus* **2020**, *29*, 569–577. [[CrossRef](#)]
106. Li, Y.; Jia, R.; Liu, Y.; Tang, S.; Ma, X.; Shi, L.; Zhao, J.; Hu, F.; Li, Z. Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. *Lupus* **2020**, *29*, 239–247. [[CrossRef](#)]
107. Kinloch, A.J.; Kaiser, Y.; Wolfgeher, D.; Ai, J.; Eklund, A.; Clark, M.R.; Grunewald, J. In Situ Humoral Immunity to Vimentin in HLA-DRB1\*03(+) Patients With Pulmonary Sarcoidosis. *Front. Immunol.* **2018**, *9*, 1516. [[CrossRef](#)]
108. Li, F.J.; Surolija, R.; Li, H.; Wang, Z.; Kulkarni, T.; Liu, G.; de Andrade, J.A.; Kass, D.J.; Thannickal, V.J.; Duncan, S.R.; et al. Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. *J. Immunol.* **2017**, *199*, 1596–1605. [[CrossRef](#)]
109. Ortona, E.; Capozzi, A.; Colasanti, T.; Conti, F.; Alessandri, C.; Longo, A.; Garofalo, T.; Margutti, P.; Misasi, R.; Khamashta, M.A.; et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. *Blood* **2010**, *116*, 2960–2967. [[CrossRef](#)]
110. Oldstone, M.B. Molecular mimicry: Its evolution from concept to mechanism as a cause of autoimmune diseases. *Monoclon. Antibodies Immunodiagn. Immunother.* **2014**, *33*, 158–165. [[CrossRef](#)] [[PubMed](#)]
111. Kraus, W.; Seyer, J.M.; Beachey, E.H. Vimentin-cross-reactive epitope of type 12 streptococcal M protein. *Infect. Immun.* **1989**, *57*, 2457–2461. [[CrossRef](#)] [[PubMed](#)]

112. Fujinami, R.S.; Oldstone, M.B.; Wroblewska, Z.; Frankel, M.E.; Koprowski, H. Molecular mimicry in virus infection: Crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. *Proc. Natl. Acad. Sci. USA* **1983**, *80*, 2346–2350. [[CrossRef](#)]
113. Dales, S.; Fujinami, R.S.; Oldstone, M.B. Infection with vaccinia favors the selection of hybridomas synthesizing autoantibodies against intermediate filaments, one of them cross-reacting with the virus hemagglutinin. *J. Immunol.* **1983**, *131*, 1546–1553. [[PubMed](#)]
114. Su, L.; Pan, P.; Yan, P.; Long, Y.; Zhou, X.; Wang, X.; Zhou, R.; Wen, B.; Xie, L.; Liu, D. Role of vimentin in modulating immune cell apoptosis and inflammatory responses in sepsis. *Sci. Rep.* **2019**, *9*, 5747. [[CrossRef](#)] [[PubMed](#)]
115. Kumar, Y.; Valdivia, R.H. Actin and intermediate filaments stabilize the Chlamydia trachomatis vacuole by forming dynamic structural scaffolds. *Cell Host Microbe* **2008**, *4*, 159–169. [[CrossRef](#)]
116. He, C.; Kong, L.; Zhou, L.; Xia, J.; Wei, H.; Liu, M.; Peng, H. Host Cell Vimentin Restrains Toxoplasma gondii Invasion and Phosphorylation of Vimentin is Partially Regulated by Interaction with TgROP18. *Int. J. Biol. Sci.* **2017**, *13*, 1126–1137. [[CrossRef](#)] [[PubMed](#)]
117. Novoa, R.R.; Calderita, G.; Arranz, R.; Fontana, J.; Granzow, H.; Risco, C. Virus factories: Associations of cell organelles for viral replication and morphogenesis. *Biol. Cell* **2005**, *97*, 147–172. [[CrossRef](#)]
118. Babrak, L.; Danelishvili, L.; Rose, S.J.; Kornberg, T.; Bermudez, L.E. The environment of “Mycobacterium avium subsp. hominissuis” microaggregates induces synthesis of small proteins associated with efficient infection of respiratory epithelial cells. *Infect. Immun.* **2015**, *83*, 625–636. [[CrossRef](#)]
119. Mak, T.N.; Fischer, N.; Laube, B.; Brinkmann, V.; Metruccio, M.M.; Sfanos, K.S.; Mollenkopf, H.J.; Meyer, T.F.; Bruggemann, H. Propionibacterium acnes host cell tropism contributes to vimentin-mediated invasion and induction of inflammation. *Cell Microbiol.* **2012**, *14*, 1720–1733. [[CrossRef](#)]
120. Broers, J.L.; de Leij, L.; Rot, M.K.; ter Haar, A.; Lane, E.B.; Leigh, I.M.; Wagenaar, S.S.; Vooijs, G.P.; Ramaekers, F.C. Expression of intermediate filament proteins in fetal and adult human lung tissues. *Differ. Res. Biol. Divers.* **1989**, *40*, 119–128. [[CrossRef](#)]
121. Yang, Y.; Riccio, P.; Schotsaert, M.; Mori, M.; Lu, J.; Lee, D.K.; Garcia-Sastre, A.; Xu, J.; Cardoso, W.V. Spatial-Temporal Lineage Restrictions of Embryonic p63(+) Progenitors Establish Distinct Stem Cell Pools in Adult Airways. *Dev. Cell* **2018**, *44*, 752–761 e754. [[CrossRef](#)] [[PubMed](#)]
122. Bastounis, E.E.; Yeh, Y.T.; Theriot, J.A. Matrix stiffness modulates infection of endothelial cells by Listeria monocytogenes via expression of cell surface vimentin. *Mol. Biol. Cell* **2018**, *29*, 1571–1589. [[CrossRef](#)] [[PubMed](#)]
123. Ghosh, P.; Halvorsen, E.M.; Ammendolia, D.A.; Mor-Vaknin, N.; O’Riordan, M.X.D.; Brumell, J.H.; Markovitz, D.M.; Higgins, D.E. Invasion of the Brain by Listeria monocytogenes Is Mediated by InlF and Host Cell Vimentin. *mBio* **2018**, *9*, e00160-18. [[CrossRef](#)] [[PubMed](#)]
124. Huang, S.H.; Chi, F.; Peng, L.; Bo, T.; Zhang, B.; Liu, L.Q.; Wu, X.; Mor-Vaknin, N.; Markovitz, D.M.; Cao, H.; et al. Vimentin, a Novel NF-kappaB Regulator, Is Required for Meningitic Escherichia coli K1-Induced Pathogen Invasion and PMN Transmigration across the Blood-Brain Barrier. *PLoS ONE* **2016**, *11*, e0162641. [[CrossRef](#)]
125. Guignot, J.; Servin, A.L. Maintenance of the Salmonella-containing vacuole in the juxtannuclear area: A role for intermediate filaments. *Microb. Pathog.* **2008**, *45*, 415–422. [[CrossRef](#)]
126. Icenogle, L.M.; Hengel, S.M.; Coye, L.H.; Streifel, A.; Collins, C.M.; Goodlett, D.R.; Moseley, S.L. Molecular and biological characterization of Streptococcal SpyA-mediated ADP-ribosylation of intermediate filament protein vimentin. *J. Biol. Chem.* **2012**, *287*, 21481–21491. [[CrossRef](#)]
127. Rohrbeck, A.; Schroder, A.; Hagemann, S.; Pich, A.; Holtje, M.; Ahnert-Hilger, G.; Just, I. Vimentin mediates uptake of C3 exoenzyme. *PLoS ONE* **2014**, *9*, e101071. [[CrossRef](#)]
128. Rohrbeck, A.; Holtje, M.; Adolf, A.; Oms, E.; Hagemann, S.; Ahnert-Hilger, G.; Just, I. The Rho ADP-ribosylating C3 exoenzyme binds cells via an Arg-Gly-Asp motif. *J. Biol. Chem.* **2017**, *292*, 17668–17680. [[CrossRef](#)]
129. Schafer, G.; Graham, L.M.; Lang, D.M.; Blumenthal, M.J.; Bergant Marusic, M.; Katz, A.A. Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions. *J. Virol.* **2017**, *91*, e00307–e00317. [[CrossRef](#)]

130. Wu, W.; Pante, N. Vimentin plays a role in the release of the influenza A viral genome from endosomes. *Virology* **2016**, *497*, 41–52. [[CrossRef](#)]
131. Huang, S.Y.; Huang, C.H.; Chen, C.J.; Chen, T.W.; Lin, C.Y.; Lin, Y.T.; Kuo, S.M.; Huang, C.G.; Lee, L.A.; Chen, Y.H.; et al. Novel Role for miR-1290 in Host Species Specificity of Influenza A Virus. *Mol. Ther. Nucleic Acids* **2019**, *17*, 10–23. [[CrossRef](#)] [[PubMed](#)]
132. Teo, C.S.; Chu, J.J. Cellular vimentin regulates construction of dengue virus replication complexes through interaction with NS4A protein. *J. Virol.* **2014**, *88*, 1897–1913. [[CrossRef](#)] [[PubMed](#)]
133. Risco, C.; Rodriguez, J.R.; Lopez-Iglesias, C.; Carrascosa, J.L.; Esteban, M.; Rodriguez, D. Endoplasmic reticulum–Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. *J. Virol.* **2002**, *76*, 1839–1855. [[CrossRef](#)] [[PubMed](#)]
134. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* **2003**, *426*, 450–454. [[CrossRef](#)] [[PubMed](#)]
135. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Kruger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.H.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **2020**, *181*, 271–280. [[CrossRef](#)] [[PubMed](#)]
136. Glowacka, I.; Bertram, S.; Muller, M.A.; Allen, P.; Soilleux, E.; Pfefferle, S.; Steffen, I.; Tsegaye, T.S.; He, Y.; Gnirss, K.; et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J. Virol.* **2011**, *85*, 4122–4134. [[CrossRef](#)]
137. Matsuyama, S.; Nagata, N.; Shirato, K.; Kawase, M.; Takeda, M.; Taguchi, F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. *J. Virol.* **2010**, *84*, 12658–12664. [[CrossRef](#)]
138. Ye, J.; Zhang, B.; Xu, J.; Chang, Q.; McNutt, M.A.; Korteweg, C.; Gong, E.; Gu, J. Molecular pathology in the lungs of severe acute respiratory syndrome patients. *Am. J. Pathol.* **2007**, *170*, 538–545. [[CrossRef](#)]
139. Mossel, E.C.; Wang, J.; Jeffers, S.; Edeen, K.E.; Wang, S.; Cosgrove, G.P.; Funk, C.J.; Manzer, R.; Miura, T.A.; Pearson, L.D.; et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. *Virology* **2008**, *372*, 127–135. [[CrossRef](#)]
140. Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; O’Meara, M.J.; Guo, J.Z.; Swaney, D.L.; Tummino, T.A.; Huttenhain, R.; et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. *BioRxiv* **2020**, 10.1101. [[CrossRef](#)]
141. Ziegler, C.G.K.; Allon, S.J.; Nyquist, S.K.; Shalek, A.K.; Ordovas-Montanes, J.; Network, H.L.B. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. *Cell* **2020**, *181*, 1016–1035. [[CrossRef](#)] [[PubMed](#)]
142. Sungnak, W.; Huang, N.; Becavin, C.; Berg, M.; Queen, R.; Litvinukova, M.; Talavera-Lopez, C.; Maatz, H.; Reichart, D.; Sampaziotis, F.; et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat. Med.* **2020**, *26*, 681–687. [[CrossRef](#)] [[PubMed](#)]
143. Kasper, M.; Stosiek, P. The expression of vimentin in epithelial cells from human nasal mucosa. *Eur. Arch. Otorhinolaryngol.* **1990**, *248*, 53–56. [[CrossRef](#)] [[PubMed](#)]
144. Hamming, I.; Timens, W.; Bulthuis, M.L.; Lely, A.T.; Navis, G.; van Goor, H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **2004**, *203*, 631–637. [[CrossRef](#)] [[PubMed](#)]
145. Ma, D.; Chen, C.B.; Jhanji, V.; Xu, C.; Yuan, X.L.; Liang, J.J.; Huang, Y.; Cen, L.P.; Ng, T.K. Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea. *Eye* **2020**, *34*, 1212–1219. [[CrossRef](#)]
146. Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* **2020**, *395*, 1417–1418. [[CrossRef](#)]
147. Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K.Y.; et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* **2020**, *181*, 894–904. [[CrossRef](#)]

148. Yang, J.; Zou, L.; Yang, Y.; Yuan, J.; Hu, Z.; Liu, H.; Peng, H.; Shang, W.; Zhang, X.; Zhu, J.; et al. Superficial vimentin mediates DENV-2 infection of vascular endothelial cells. *Sci. Rep.* **2016**, *6*, 38372. [[CrossRef](#)]
149. Liang, J.J.; Yu, C.Y.; Liao, C.L.; Lin, Y.L. Vimentin binding is critical for infection by the virulent strain of Japanese encephalitis virus. *Cell Microbiol.* **2011**, *13*, 1358–1370. [[CrossRef](#)]
150. Das, S.K.; Gupta, I.; Cho, Y.K.; Zhang, X.; Uehara, H.; Muddana, S.K.; Bernhisel, A.A.; Archer, B.; Ambati, B.K. Vimentin knockdown decreases corneal opacity. *Investig. Ophthalmol. Vis. Sci.* **2014**, *55*, 4030–4040. [[CrossRef](#)]
151. Kim, J.K.; Fahad, A.M.; Shanmukhappa, K.; Kapil, S. Defining the cellular target(s) of porcine reproductive and respiratory syndrome virus blocking monoclonal antibody 7G10. *J. Virol.* **2006**, *80*, 689–696. [[CrossRef](#)] [[PubMed](#)]
152. Koudelka, K.J.; Destito, G.; Plummer, E.M.; Trauger, S.A.; Siuzdak, G.; Manchester, M. Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. *PLoS Pathog.* **2009**, *5*, e1000417. [[CrossRef](#)] [[PubMed](#)]
153. Kavathekar, V.K.; Dhanavade, M.J.; Sonawane, K.D.; Balakrishnan, A. Role of cell surface vimentin in Chandipura virus replication in Neuro-2a cells. *Virus Res.* **2020**, *285*, 198014. [[CrossRef](#)]
154. Turkki, P.; Laajala, M.; Flodstrom-Tullberg, M.; Marjomaki, V. Human Enterovirus Group B Viruses Rely on Vimentin Dynamics for Efficient Processing of Viral Nonstructural Proteins. *J. Virol.* **2020**, *94*, e01393-01319. [[CrossRef](#)] [[PubMed](#)]
155. Ma, X.; Ling, Y.; Li, P.; Sun, P.; Cao, Y.; Bai, X.; Li, K.; Fu, Y.; Zhang, J.; Li, D.; et al. Cellular Vimentin Interacts with Foot-and-Mouth Disease Virus Nonstructural Protein 3A and Negatively Modulates Viral Replication. *J. Virol.* **2020**, JVI.00273-20. [[CrossRef](#)] [[PubMed](#)]
156. Stefanovic, S.; Windsor, M.; Nagata, K.I.; Inagaki, M.; Wileman, T. Vimentin rearrangement during African swine fever virus infection involves retrograde transport along microtubules and phosphorylation of vimentin by calcium calmodulin kinase II. *J. Virol.* **2005**, *79*, 11766–11775. [[CrossRef](#)] [[PubMed](#)]
157. Nitahara-Kasahara, Y.; Fukasawa, M.; Shinkai-Ouchi, F.; Sato, S.; Suzuki, T.; Murakami, K.; Wakita, T.; Hanada, K.; Miyamura, T.; Nishijima, M. Cellular vimentin content regulates the protein level of hepatitis C virus core protein and the hepatitis C virus production in cultured cells. *Virology* **2009**, *383*, 319–327. [[CrossRef](#)]
158. DeBoer, J.; Wojtkiewicz, M.S.; Haverland, N.; Li, Y.; Harwood, E.; Leshen, E.; George, J.W.; Ciborowski, P.; Belshan, M. Proteomic profiling of HIV-infected T-cells by SWATH mass spectrometry. *Virology* **2018**, *516*, 246–257. [[CrossRef](#)]
159. Fernandez-Ortega, C.; Ramirez, A.; Casillas, D.; Paneque, T.; Ubieta, R.; Dubed, M.; Navea, L.; Castellanos-Serra, L.; Duarte, C.; Falcon, V.; et al. Identification of Vimentin as a Potential Therapeutic Target against HIV Infection. *Viruses* **2016**, *8*, 98. [[CrossRef](#)]
160. Snasel, J.; Shoeman, R.; Horejsi, M.; Hruskova-Heidingsfeldova, O.; Sedlacek, J.; Ruml, T.; Pichova, I. Cleavage of vimentin by different retroviral proteases. *Arch. Biochem. Biophys.* **2000**, *377*, 241–245. [[CrossRef](#)]
161. Alldridge, L.C.; O'Farrell, M.K.; Dealtry, G.B. Interferon beta increases expression of vimentin at the messenger RNA and protein levels in differentiated embryonal carcinoma (PSMB) cells. *Exp. Cell Res.* **1989**, *185*, 387–393. [[CrossRef](#)]
162. Lv, N.; Gao, Y.; Guan, H.; Wu, D.; Ding, S.; Teng, W.; Shan, Z. Inflammatory mediators, tumor necrosis factor-alpha and interferon-gamma, induce EMT in human PTC cell lines. *Oncol. Lett.* **2015**, *10*, 2591–2597. [[CrossRef](#)] [[PubMed](#)]
163. Geisler, F.; Leube, R.E. Epithelial Intermediate Filaments: Guardians against Microbial Infection? *Cells* **2016**, *5*, 29. [[CrossRef](#)] [[PubMed](#)]
164. Denes, C.E.; Miranda-Saksena, M.; Cunningham, A.L.; Diefenbach, R.J. Cytoskeletons in the Closet-Subversion in Alphaherpesvirus Infections. *Viruses* **2018**, *10*, 79. [[CrossRef](#)] [[PubMed](#)]
165. Ridge, K.M.; Shumaker, D.; Robert, A.; Hookway, C.; Gelfand, V.I.; Janmey, P.A.; Lowery, J.; Guo, M.; Weitz, D.A.; Kuczmariski, E.; et al. Methods for Determining the Cellular Functions of Vimentin Intermediate Filaments. *Methods Enzymol.* **2016**, *568*, 389–426. [[CrossRef](#)]
166. Strouhalova, K.; Prechova, M.; Gandalovicova, A.; Brabek, J.; Gregor, M.; Rosel, D. Vimentin Intermediate Filaments as Potential Target for Cancer Treatment. *Cancers* **2020**, *12*, 184. [[CrossRef](#)]
167. Weidle, U.H.; Maisel, D.; Klostermann, S.; Schiller, C.; Weiss, E.H. Intracellular Proteins Displayed on the Surface of Tumor Cells as Targets for Therapeutic Intervention with Antibody-related Agents. *J. Cell Sci.* **2011**, *8*, 49–64.



168. Noh, H.; Yan, J.; Hong, S.; Kong, L.Y.; Gabrusiewicz, K.; Xia, X.; Heimberger, A.B.; Li, S. Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. *Oncotarget* **2016**, *7*, 72021–72032. [[CrossRef](#)]
169. Babic, I.; Nurmemmedov, E.; Yenugonda, V.M.; Juarez, T.; Nomura, N.; Pingle, S.C.; Glassy, M.C.; Kesari, S. Pritumumab, the first therapeutic antibody for glioma patients. *Hum. Antibodies* **2018**, *26*, 95–101. [[CrossRef](#)]
170. Hugwil, A.V. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human x human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. *Med. Hypotheses* **2013**, *81*, 489–495. [[CrossRef](#)] [[PubMed](#)]
171. Huet, D.; Bagot, M.; Loyaux, D.; Capdevielle, J.; Conraux, L.; Ferrara, P.; Bensussan, A.; Marie-Cardine, A. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. *J. Immunol.* **2006**, *176*, 652–659. [[CrossRef](#)] [[PubMed](#)]
172. Hingorani, S.R.; Harris, W.P.; Beck, J.T.; Berdov, B.A.; Wagner, S.A.; Pshevlotsky, E.M.; Tjulandin, S.A.; Gladkov, O.A.; Holcombe, R.F.; Korn, R.; et al. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. *Clin. Cancer Res.* **2016**, *22*, 2848–2854. [[CrossRef](#)] [[PubMed](#)]
173. Jung, K.; Ha, Y.; Ha, S.K.; Han, D.U.; Kim, D.W.; Moon, W.K.; Chae, C. Antiviral effect of *Saccharomyces cerevisiae* beta-glucan to swine influenza virus by increased production of interferon-gamma and nitric oxide. *J. Vet. Med. BInfect. Dis. Vet. Public Health* **2004**, *51*, 72–76. [[CrossRef](#)] [[PubMed](#)]
174. Higashino-Kameda, M.; Yabe-Wada, T.; Matsuba, S.; Takeda, K.; Anzawa, K.; Mochizuki, T.; Makimura, K.; Saijo, S.; Iwakura, Y.; Toga, H.; et al. A critical role of Dectin-1 in hypersensitivity pneumonitis. *Inflamm. Res. Off. J. Eur. Histamine Res. Soc.* **2016**, *65*, 235–244. [[CrossRef](#)]
175. Mohan, R.; Bargagna-Mohan, P. The Use of Withaferin A to Study Intermediate Filaments. *Methods Enzymol.* **2016**, *568*, 187–218. [[CrossRef](#)]
176. Kaschula, C.H.; Tuveri, R.; Ngarande, E.; Dzobo, K.; Barnett, C.; Kusza, D.A.; Graham, L.M.; Katz, A.A.; Rafudeen, M.S.; Parker, M.I.; et al. The garlic compound ajoene covalently binds vimentin, disrupts the vimentin network and exerts anti-metastatic activity in cancer cells. *BMC Cancer* **2019**, *19*, 248. [[CrossRef](#)]
177. Ermakova, S.; Choi, B.Y.; Choi, H.S.; Kang, B.S.; Bode, A.M.; Dong, Z. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. *J. Biol. Chem.* **2005**, *280*, 16882–16890. [[CrossRef](#)]
178. Miyai, S.; Yamaguchi, A.; Iwasaki, T.; Shamsa, F.; Ohtsuki, K. Biochemical characterization of epigallocatechin-3-gallate as an effective stimulator for the phosphorylation of its binding proteins by glycogen synthase kinase-3beta in vitro. *Biol. Pharm. Bull.* **2010**, *33*, 1932–1937. [[CrossRef](#)]
179. Hsu, S. Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections. *Inflamm. Allergy Drug Targets* **2015**, *14*, 13–18. [[CrossRef](#)]
180. Yue, Q.; Feng, L.; Cao, B.; Liu, M.; Zhang, D.; Wu, W.; Jiang, B.; Yang, M.; Liu, X.; Guo, D. Proteomic Analysis Revealed the Important Role of Vimentin in Human Cervical Carcinoma HeLa Cells Treated With Gambogic Acid. *Mol. Cell Proteom.* **2016**, *15*, 26–44. [[CrossRef](#)]
181. Li, D.; Song, X.Y.; Yue, Q.X.; Cui, Y.J.; Liu, M.; Feng, L.X.; Wu, W.Y.; Jiang, B.H.; Yang, M.; Qu, X.B.; et al. Proteomic and bioinformatic analyses of possible target-related proteins of gambogic acid in human breast carcinoma MDA-MB-231 cells. *Chin. J. Nat. Med.* **2015**, *13*, 41–51. [[CrossRef](#)]
182. Qu, Y.; Zhang, G.; Ji, Y.; Zhua, H.; Lv, C.; Jiang, W. Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo. *Phytomed.: Int. J. Phytother. Phytopharm.* **2016**, *23*, 350–358. [[CrossRef](#)] [[PubMed](#)]
183. Trogden, K.P.; Battaglia, R.A.; Kabiraj, P.; Madden, V.J.; Herrmann, H.; Snider, N.T. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. *FASEB J.* **2018**, *32*, 2841–2854. [[CrossRef](#)] [[PubMed](#)]
184. Nikolova, M.; Tawab, A.; Marie-Cardine, A.; Bagot, M.; Boumsell, L.; Bensussan, A. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells. *J. Investig. Derm.* **2001**, *116*, 731–738. [[CrossRef](#)]
185. Glassy, M.C.; Hagiwara, H. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. *Hum. Antibodies* **2009**, *18*, 127–137. [[CrossRef](#)]
186. Sager, P.R.; Matheson, D.W. Mechanisms of neurotoxicity related to selective disruption of microtubules and intermediate filaments. *Toxicology* **1988**, *49*, 479–492. [[CrossRef](#)]

187. Arocena, M. Effect of acrylamide on the cytoskeleton and apoptosis of bovine lens epithelial cells. *Cell Biol. Int.* **2006**, *30*, 1007–1012. [[CrossRef](#)]
188. Galigniana, M.D.; Scruggs, J.L.; Herrington, J.; Welsh, M.J.; Carter-Su, C.; Housley, P.R.; Pratt, W.B. Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. *Mol. Endocrinol.* **1998**, *12*, 1903–1913. [[CrossRef](#)]
189. Stamatakis, K.; Sánchez-Gómez, F.J.; Pérez-Sala, D. Identification of novel protein targets for modification by 15-deoxy- $\Delta^{12,14}$ -prostaglandin J<sub>2</sub> in mesangial cells reveals multiple interactions with the cytoskeleton. *J. Am. Soc. Nephrol.* **2006**, *17*, 89–98. [[CrossRef](#)]
190. Santoro, M.G. Antiviral activity of cyclopentenone prostanoids. *Trends Microbiol.* **1997**, *5*, 276–281. [[CrossRef](#)]
191. Bargagna-Mohan, P.; Hamza, A.; Kim, Y.E.; Khuan Abby Ho, Y.; Mor-Vaknin, N.; Wendschlag, N.; Liu, J.; Evans, R.M.; Markovitz, D.M.; Zhan, C.G.; et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. *Chem. Biol.* **2007**, *14*, 623–634. [[CrossRef](#)] [[PubMed](#)]
192. Grin, B.; Mahammad, S.; Wedig, T.; Cleland, M.M.; Tsai, L.; Herrmann, H.; Goldman, R.D. Withaferin A alters intermediate filament organization, cell shape and behavior. *PLoS ONE* **2012**, *7*, e39065. [[CrossRef](#)] [[PubMed](#)]
193. Yang, J.; Yan, W.; Li, Y.; Niu, L.; Ye, H.; Chen, L. The Natural Compound Withaferin A Covalently Binds to Cys239 of beta-Tubulin to Promote Tubulin Degradation. *Mol. Pharm.* **2019**, *96*, 711–719. [[CrossRef](#)] [[PubMed](#)]
194. Bollong, M.J.; Pietila, M.; Pearson, A.D.; Sarkar, T.R.; Ahmad, I.; Soundararajan, R.; Lyssiotis, C.A.; Mani, S.A.; Schultz, P.G.; Lairson, L.L. A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E9903–E9912. [[CrossRef](#)] [[PubMed](#)]
195. Pérez-Sala, D.; Mollinedo, F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. *Biochem. Biophys. Res. Commun.* **1994**, *199*, 1209–1215. [[CrossRef](#)] [[PubMed](#)]
196. Pérez-Sala, D.; Collado-Escobar, D.; Mollinedo, F. Intracellular Alkalinization Suppresses Lovastatin-induced Apoptosis in HL-60 Cells through the Inactivation of a pH-dependent Endonuclease. *J. Biol. Chem.* **1995**, *270*, 6235–6242. [[CrossRef](#)]
197. Kanugula, A.K.; Dhople, V.M.; Volker, U.; Ummanni, R.; Kotamraju, S. Fluvastatin mediated breast cancer cell death: A proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells. *PLoS ONE* **2014**, *9*, e108890. [[CrossRef](#)]
198. Fedson, D.S.; Opal, S.M.; Rordam, O.M. Hiding in Plain Sight: An Approach to Treating Patients with Severe COVID-19 Infection. *mBio* **2020**, *11*, e00398-00320. [[CrossRef](#)]
199. Esposito, A.M.; Cheung, P.; Swartz, T.H.; Li, H.; Tsibane, T.; Durham, N.D.; Basler, C.F.; Felsenfeld, D.P.; Chen, B.K. A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry. *Virology* **2016**, *490*, 6–16. [[CrossRef](#)]
200. España, E.; Nam, J.H.; Song, E.J.; Song, D.; Lee, C.K.; Kim, J.K. Lipophilic statins inhibit Zika virus production in Vero cells. *Sci. Rep.* **2019**, *9*, 11461. [[CrossRef](#)]
201. Caly, L.; Druce, J.D.; Catton, M.G.; Jans, D.A.; Wagstaff, K.M. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antivir. Res.* **2020**, *178*, 104787. [[CrossRef](#)] [[PubMed](#)]
202. Lin, Y.C.; Broedersz, C.P.; Rowat, A.C.; Wedig, T.; Herrmann, H.; Mackintosh, F.C.; Weitz, D.A. Divalent cations crosslink vimentin intermediate filament tail domains to regulate network mechanics. *J. Mol. Biol.* **2010**, *399*, 637–644. [[CrossRef](#)] [[PubMed](#)]
203. Monico, A.; Zorrilla, S.; Rivas, G.; Perez-Sala, D. Zinc Differentially Modulates the Assembly of Soluble and Polymerized Vimentin. *Int. J. Mol. Sci.* **2020**, *21*, 2426. [[CrossRef](#)] [[PubMed](#)]
204. Zhu, H.; Cao, Y.; Su, W.; Huang, S.; Lu, W.; Zhou, Y.; Gao, J.; Zhao, W.; Zhang, B.; Wu, X. Enterovirus A71 VP1 Variation A289T Decreases the Central Nervous System Infectivity via Attenuation of Interactions between VP1 and Vimentin In Vitro and In Vivo. *Viruses* **2019**, *11*, 467. [[CrossRef](#)] [[PubMed](#)]
205. Fu, Y.; He, S.; Waheed, A.A.; Dabbagh, D.; Zhou, Z.; Trinite, B.; Wang, Z.; Yu, J.; Wang, D.; Li, F.; et al. PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 9537–9545. [[CrossRef](#)] [[PubMed](#)]
206. Zamay, T.N.; Kolovskaya, O.S.; Glazyrin, Y.E.; Zamay, G.S.; Kuznetsova, S.A.; Spivak, E.A.; Wehbe, M.; Savitskaya, A.G.; Zubkova, O.A.; Kadkina, A.; et al. DNA-aptamer targeting vimentin for tumor therapy in vivo. *Nucleic Acid Ther.* **2014**, *24*, 160–170. [[CrossRef](#)]

207. Jalalian, S.H.; Ramezani, M.; Abnous, K.; Taghdisi, S.M. Targeted co-delivery of epirubicin and NAS-24 aptamer to cancer cells using selenium nanoparticles for enhancing tumor response in vitro and in vivo. *Cancer Lett.* **2018**, *416*, 87–93. [[CrossRef](#)]
208. Yoon, S.; Armstrong, B.; Habib, N.; Rossi, J.J. Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis. *Mol. Cancer Res. MCR* **2017**, *15*, 811–820. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).